TW202110415A - Packaging bottle and packaging kit for injection, and filling, stoppering and capping device and method - Google Patents
Packaging bottle and packaging kit for injection, and filling, stoppering and capping device and method Download PDFInfo
- Publication number
- TW202110415A TW202110415A TW109130514A TW109130514A TW202110415A TW 202110415 A TW202110415 A TW 202110415A TW 109130514 A TW109130514 A TW 109130514A TW 109130514 A TW109130514 A TW 109130514A TW 202110415 A TW202110415 A TW 202110415A
- Authority
- TW
- Taiwan
- Prior art keywords
- bottle
- layer
- rubber stopper
- injection
- ast
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B3/00—Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B7/00—Closing containers or receptacles after filling
- B65B7/16—Closing semi-rigid or rigid containers or receptacles not deformed by, or not taking-up shape of, contents, e.g. boxes or cartons
- B65B7/28—Closing semi-rigid or rigid containers or receptacles not deformed by, or not taking-up shape of, contents, e.g. boxes or cartons by applying separate preformed closures, e.g. lids, covers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D39/00—Closures arranged within necks or pouring openings or in discharge apertures, e.g. stoppers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D51/00—Closures not otherwise provided for
- B65D51/18—Arrangements of closures with protective outer cap-like covers or of two or more co-operating closures
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D53/00—Sealing or packing elements; Sealings formed by liquid or plastics material
- B65D53/04—Discs
Landscapes
- Engineering & Computer Science (AREA)
- Mechanical Engineering (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Closures For Containers (AREA)
Abstract
Description
本發明涉及對專利申請PCT/US2016/021581,公開號WO2016145092A1,對應中國申請號2016800150788,公開號CN107530556A所公開的化合物TH-2870以及PCT/US2016/062114,公開號WO2017087428A1,對應中國申請號2016800446081,公開號CN108290911A中的S構型化合物的注射液製劑的研發,特別是專為該注射液製劑研發的專屬包裝瓶,屬於藥品包裝領域。The present invention relates to a patent application PCT/US2016/021581, publication number WO2016145092A1, corresponding to Chinese application number 2016800150788, publication number CN107530556A disclosed compound TH-2870 and PCT/US2016/062114, publication number WO2017087428A1, corresponding to Chinese application number 2016800446081, published The research and development of the injection preparation of the S configuration compound in No. CN108290911A, especially the exclusive packaging bottle specially developed for the injection preparation, belongs to the field of pharmaceutical packaging.
我公司(大陸商深圳艾欣達偉醫藥科技有限公司)開發的以過表達醛酮還原酶1C3(AKR1C3)為標靶的DNA烷化癌症治療藥物AST-3424 (參見專利申請:DNA烷化劑,對應PCT申請號PCT/US2016/021581, 公開號WO2016/145092,對應中國申請號2016800150788,公開號CN107530556A中公開化合物TH2870;(R)-及(S)-1-(3-(3-N, N-二甲基胺基羰基)苯氧基-4-硝苯基)-1-乙基-N, N’-雙(伸乙基)胺基磷酸酯、組合物及其使用及製備方法,對應PCT申請號PCT/US2016/062114、公開號WO2017087428A1,對應中國申請號2016800446081、公開號CN108290911A中的S構型化合物),中文名為(S)-1-(3-(3-N, N-二甲氨基羰基)苯氧基-4-硝基苯基)-1-乙基-N, N'-雙(亞乙基)氨基磷酸酯,也稱為OBI-3424、TH-2870的S構型化合物),CAS號為2097713-69-2,其結構如下: AST-3424的化學結構式The DNA alkylation cancer therapeutic drug AST-3424 developed by our company (Mainland China Shenzhen Aixindawei Pharmaceutical Technology Co., Ltd.) targets the overexpression of aldehyde ketone reductase 1C3 (AKR1C3) (see patent application: DNA alkylating agent, Corresponding to PCT application number PCT/US2016/021581, publication number WO2016/145092, corresponding to Chinese application number 2016800150788, publication number CN107530556A discloses compound TH2870; (R)- and (S)-1-(3-(3-N, N -Dimethylaminocarbonyl)phenoxy-4-nitrophenyl)-1-ethyl-N, N'-bis(ethylene)amino phosphate, composition and its use and preparation method, corresponding PCT application number PCT/US2016/062114, publication number WO2017087428A1, corresponding to Chinese application number 2016800446081, the S configuration compound in publication number CN108290911A), the Chinese name is (S)-1-(3-(3-N, N-二) Methylaminocarbonyl)phenoxy-4-nitrophenyl)-1-ethyl-N, N'-bis(ethylene) phosphoramidate, also known as the S configuration of OBI-3424 and TH-2870 Compound), CAS number is 209713-69-2, and its structure is as follows: The chemical structure of AST-3424
已有行業權威文獻(Kathryn Evans, Jian Xin Duan, Tara Pritchard, et al. OBI-3424, a novel AKR1C3-activated prodrug, exhibits potent efficacy against preclinical models of T-ALL [J], Clinical Cancer Research, 2019, DOI: 10. 1158/1078-0432. CCR-19-0551; Richard B. Lock, Kathryn Evans, Raymond Yung, Tara Pritchard, Beverly A. Teicher, Jian Xin Duan, Yuelong Guo, Stephen W. Erickson and Malcolm A. Smith, Abstract LB-B16:The AKR1C3-Activated Prodrug OBI-3424 Exerts Profound In Vivo Efficacy Against Preclinical Models of T-Cell Acute Lymphoblastic Leukemia (T-ALL); a Pediatric Preclinical Testing Consortium Study [C], AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; October 26-30, 2017; Philadelphia, PA, DOI: 10. 1158/1535-7163. )證實該化合物為一種廣譜的小分子抗癌前藥,對多種實體腫瘤和血液腫瘤具有療效。There have been industry authoritative documents (Kathryn Evans, Jian Xin Duan, Tara Pritchard, et al. OBI-3424, a novel AKR1C3-activated prodrug, exhibits potent efficacy against preclinical models of T-ALL [J], Clinical Cancer Research, 2019, DOI: 10. 1158/1078-0432. CCR-19-0551; Richard B. Lock, Kathryn Evans, Raymond Yung, Tara Pritchard, Beverly A. Teicher, Jian Xin Duan, Yuelong Guo, Stephen W. Erickson and Malcolm A. Smith, Abstract LB-B16:The AKR1C3-Activated Prodrug OBI-3424 Exerts Profound In Vivo Efficacy Against Preclinical Models of T-Cell Acute Lymphoblastic Leukemia (T-ALL); a Pediatric Preclinical Testing Consortium Study [C], AACR-NCI- EORTC International Conference: Molecular Targets and Cancer Therapeutics; October 26-30, 2017; Philadelphia, PA, DOI: 10. 1158/1535-7163.) confirmed that the compound is a broad-spectrum small molecule anti-cancer prodrug, which is effective against multiple entities Tumors and hematological tumors have curative effects.
為了進行後續的臨床試驗,需要製備合適的劑型進行人體給藥:通常是口服或是注射給藥。In order to carry out subsequent clinical trials, it is necessary to prepare a suitable dosage form for human administration: usually oral or injection administration.
在合成製備過程中發現該物質為淡黃色油狀物,在儲運、製劑方面存在著多種困難:由於醯胺、磷酸酯結構使得口服給藥劑型的片劑和口服液劑型開發不便,然而研發團隊初步試驗發現常規的以水作為溶劑的注射液穩定性不夠,無法滿足後續多中心、多樣本的長期臨床試驗和商業生產銷售的要求。During the synthesis and preparation process, it was found that the substance was a light yellow oily substance, and there were many difficulties in storage, transportation and preparation: due to the structure of amide and phosphate ester, the development of tablets and oral liquid dosage forms for oral administration was inconvenient. However, research and development The team’s preliminary experiment found that the stability of conventional injections that use water as a solvent is not enough to meet the requirements of follow-up multi-center, multi-sample long-term clinical trials and commercial production and sales.
經過實驗研究發現該化合物能較好的溶解在乙醇等類似溶劑體系中,因此乙醇和丙二醇等溶劑所製備的濃縮注射液製劑具有較高含量的乙醇,同時注射劑依然較之常規的水基注射液流動相弱,比較黏稠,常規使用的水基注射液的包裝瓶(藥水瓶或安剖瓶)的結構不能滿足要求:After experimental research, it is found that the compound can be better dissolved in similar solvent systems such as ethanol. Therefore, concentrated injection preparations prepared from solvents such as ethanol and propylene glycol have a higher content of ethanol. At the same time, the injection is still better than conventional water-based injections. The mobile phase is weak and viscous. The structure of the conventionally used water-based injection packaging bottle (medicine bottle or ampoule bottle) cannot meet the requirements:
如圖8所示,典型的藥水瓶(vial)(參見中國新型公告書明書CN201445645U,公開日2010.05.05)包括瓶體1、膠塞2以及封蓋3,有時也會在封蓋設置保護蓋4。由於使用的膠塞多為橡膠材質,AST-3424化合物的性質比較活潑,因此橡膠極有可能與注射液接觸後,使得橡膠溶解在乙醇中,進而影響注射液的穩定性。As shown in Figure 8, a typical vial (refer to the Chinese New Bulletin CN201445645U, publication date 2010.05.05) includes a
一種可能的應對策略是在常規的膠塞2上進行覆膜,典型的覆膜後的膠塞(參見中國實用新型公開檔CN2612625Y,公開日2004.04.21)結構如圖9所示,該覆膜膠塞包括基體5、塞體6以及覆膜7。A possible response strategy is to cover the
顯然通過在塞體6的表面塗覆覆膜7來隔離乙醇/丙二醇溶劑的AST-3424注射液來保證注射液的包裝穩定性是一個比較合適、經濟的選擇。Obviously, it is a more suitable and economical choice to ensure the packaging stability of the injection solution by coating the
現有的覆膜膠塞是直接通過覆膜或黏附劑將膜材料直接結合在膠塞外表面的。使用時:需要使用注射器針頭刺破該覆膜,然後吸取預定體積的注射液,如此就有兩次穿刺通過這個覆膜,而由於覆膜是黏附結合在膠塞外表的,穿刺過程中存在污染的風險。The existing film-coated rubber stoppers directly bond the film material to the outer surface of the rubber stopper through a film or an adhesive. When in use: Need to use a syringe needle to pierce the membrane, and then suck a predetermined volume of injection, so that there are two punctures through the membrane, and because the membrane is adhered to the surface of the rubber stopper, there is contamination during the puncture process risks of.
行業上對於藥液,無論是用於注射給藥的注射劑或是口服給藥的口服液都是使用上述圖8、9的結構進行包裝。In the industry, the liquid medicine, whether it is an injection for injection administration or an oral liquid for oral administration, is packaged with the structure of the above-mentioned Figures 8 and 9.
然而上述的包裝存在一個問題,無法通過外觀快速的知道是否被使用:對於注射劑或口服液,雖然取下保護蓋後即意味著包裝被拆封,但是否有被注射器針頭刺入吸取過藥液或是注入過其他物質,都是不容易快速察覺的。當然通過仔細觀察膠塞2上的針眼可以發現,但耗時而且麻煩。However, there is a problem with the above packaging. It is impossible to quickly know whether it has been used by its appearance: for injections or oral liquids, although the protective cover is removed, it means that the packaging is unsealed, but whether the syringe needle has been pierced and sucked by the liquid Or if it has been injected with other substances, it is not easy to detect quickly. Of course, it can be found by carefully observing the needle eye on the
另外,對於該種結構的包裝瓶的密封效果,由於是將膠塞塞在瓶體的瓶口上,然後加上封蓋3進行固定壓合,但在長時間的儲存中,如果發生洩漏導致藥液變質,通過肉眼的觀察也是無法快速、直觀的判斷的。In addition, for the sealing effect of the packaging bottle with this structure, because the rubber stopper is plugged on the bottle mouth of the bottle body, and then the
尋找合適的隔離乙醇/丙二醇溶劑的AST-3424注射液的包裝瓶以保證注射液與包裝瓶塞之間無污染的穩定性是本發明的課題,而其中的膠塞覆膜結構是關鍵。It is the subject of the present invention to find a suitable packaging bottle of AST-3424 injection that isolates the ethanol/propylene glycol solvent to ensure the stability of the injection and the packaging bottle stopper without contamination, and the rubber stopper film structure is the key.
通過調查,市面上具有的成膜材料比較多,經過前期醫藥用材料篩選,得出最常用、易得的幾種醫藥用材料:聚醚碸樹脂PES、聚四氟乙烯PTFE、聚偏二氟乙烯PVDF、四氟乙烯/六氟丙烯的共聚物FEP的不同牌號的膜材進行實驗。Through investigation, there are many film-forming materials on the market. After the preliminary screening of medical materials, the most commonly used and easily available medical materials are obtained: polyether resin PES, polytetrafluoroethylene PTFE, polyvinylidene difluoride Experiments were carried out on membrane materials of different grades of ethylene PVDF, tetrafluoroethylene/hexafluoropropylene copolymer FEP.
實驗使用的是以下商業可購買的膜材,具體情況如下表:
表1:不同材質、不同牌號的過濾膜材參數表
實驗中是使用對應材料的膜進行浸泡或者過濾膜進行過濾來模擬乙醇/丙二醇溶劑的AST-3424注射液的相互作用對注射液穩定性的影響。In the experiment, the membrane of the corresponding material was used for soaking or the filter membrane was used for filtration to simulate the influence of the interaction of the ethanol/propylene glycol solvent AST-3424 injection on the stability of the injection.
經過實驗證明,實質由0.75 ml的無水乙醇和0.25 ml的無水丙二醇以及10 mg的AST-3424原料藥這樣比例的溶劑、原料藥組成注射劑是穩定的,本實驗即用該注射劑來進行實驗驗證。Experiments have proved that the injection is essentially a solvent and bulk drug composed of 0.75 ml of absolute ethanol, 0.25 ml of anhydrous propylene glycol and 10 mg of AST-3424 bulk drug. This injection is used for experimental verification.
實驗驗證中的覆膜對照組使用的是聚四氟乙烯覆膜(通過黏附劑黏附)的膠塞。In the experimental verification, the coated control group used a rubber stopper with a polytetrafluoroethylene coated (adhered through an adhesive).
製備未經過濾的AST-3424注射液:由75 ml的無水乙醇和25 ml的無水丙二醇以及1 g的AST-3424原料藥這樣比例的溶劑、原料藥溶解製備100 ml的AST-3424注射液。Preparation of unfiltered AST-3424 injection: 100 ml of AST-3424 injection is prepared by dissolving 75 ml of absolute ethanol, 25 ml of anhydrous propylene glycol, and 1 g of AST-3424 bulk drug in the ratio of solvent and bulk drug.
分別通過固定在玻璃濾器支架上的不同材質、牌號的過濾膜過濾AST-3424注射液:收集通過膜過濾得到的第一個10 ml AST-3424濾液作為初始濾液,收集剩餘部分作為最終濾液。Filter AST-3424 injection through filtration membranes of different materials and brands fixed on the glass filter holder: collect the first 10 ml AST-3424 filtrate obtained through membrane filtration as the initial filtrate, and collect the remaining part as the final filtrate.
未過濾的AST-3424注射液用作空白對照液。Unfiltered AST-3424 injection was used as a blank control solution.
四氟乙烯/六氟丙烯的共聚物FEP膜組對應的FEP-1、FEP-2、FEP-3分別是浸泡在AST-3424注射液後8小時後的溶液。The FEP-1, FEP-2, and FEP-3 corresponding to the tetrafluoroethylene/hexafluoropropylene copolymer FEP film group are the solutions after immersing in the AST-3424 injection for 8 hours.
覆膜對照組浸泡液,使用的是聚醚碸樹脂、聚四氟乙烯覆膜、聚偏二氟乙烯通過黏附劑黏附的膠塞浸泡到上述的10 ml的AST-3424中,其時間為8小時。The film-coated control group soaking solution uses polyether resin, polytetrafluoroethylene film, and polyvinylidene fluoride rubber plugs adhered by an adhesive to the above 10 ml AST-3424, and the time is 8 hour.
覆膜對照組穿刺後注射液,使用聚偏二氟乙烯通過黏附劑黏附的膠塞塞進灌注有上述的AST-3424注射劑的玻璃藥水瓶口後,將1 ml注射器的針頭紮入膠塞後,通過傾斜一定角度來使得針頭與注射液解除而吸入一定體積的注射液,然後抽出針頭,將剩下的注射液在瓶體中來回顛倒兩次,打開瓶塞,直接取樣後進行分析。After the puncture injection of the coated control group, a rubber stopper adhered by polyvinylidene fluoride through an adhesive was inserted into the mouth of the glass syrup bottle filled with the above-mentioned AST-3424 injection, and the needle of a 1 ml syringe was inserted into the rubber stopper. , By tilting a certain angle to release the needle from the injection solution to inhale a certain volume of injection solution, then withdraw the needle, invert the remaining injection solution twice in the bottle body, open the bottle stopper, and directly sample and analyze.
目視檢查濾液的外觀並分析樣品中AST-3424的含量和雜質含量。Visually inspect the appearance of the filtrate and analyze the content of AST-3424 and the content of impurities in the sample.
直接的,應該根據實際的情況,將上述的不同材質、不同牌號的膜材(不是過濾膜)貼敷在膠塞上,然後將這些膠塞加蓋到裝有上述的AST-3424注射液的藥水瓶中,並按照實際使用的環境進行存放,然後在設計的24個月後取樣檢測藥水瓶中的注射液,進行HPLC檢測以考察這些膜材材質、牌號、厚度對穩定性(含量以及雜質)的影響,但實際上這樣操作不現實,為此本專案研發時使用的是加速的思路:使用上述材質、牌號、厚度、孔徑的過濾膜材的過濾操作來代替長時間接觸作用,這是由於注射液是從這些過濾膜材的過濾孔中流出,即將實際中使用的無孔的不透膜替換為透過的過濾膜來模擬強化這個長時間的接觸作用,因此以上進行的過濾膜實驗結果能夠代表膜材材質、牌號、厚度對穩定性(含量以及雜質)的影響。Directly, according to the actual situation, the above-mentioned different materials and different brands of membrane materials (not filter membranes) should be pasted on the rubber stoppers, and then these rubber stoppers should be covered with the above-mentioned AST-3424 injection solution. In the medicine bottle, and store according to the actual use environment, and then sample and test the injection in the medicine bottle after 24 months of design, and perform HPLC testing to investigate the material, brand, thickness and stability (content and impurities of these membranes) ), but in fact, this operation is unrealistic. For this reason, the idea of speeding up the development of this project is to use the filtration operation of the filter membrane material of the above-mentioned material, brand, thickness, and pore size to replace the long-term contact effect. This is Since the injection liquid flows out of the filter holes of these filter membranes, the actual non-porous impermeable membrane is replaced by a permeable filter membrane to simulate and strengthen this long-term contact effect, so the results of the filter membrane experiment performed above It can represent the influence of membrane material, brand and thickness on stability (content and impurities).
分別將上述的不同材質、不同牌號的過濾膜得到的過濾液、空白對照液、覆膜對照組浸泡液、覆膜對照組穿刺後注射液進行HPLC分析。HPLC analysis was performed on the filtrate obtained from the above-mentioned filter membranes of different materials and different brands, the blank control solution, the soaking solution of the film-coated control group, and the injection solution of the film-coated control group.
使用HPLC法測定含量:以AST-3424作為外標進行定量。HPLC method was used to determine the content: AST-3424 was used as an external standard for quantification.
UVDAD檢測器波長230nm,C18柱,柱溫25°C。UVDAD detector wavelength 230nm, C18 column, column temperature 25°C.
流動相: A:乙酸銨溶於95%水和5%乙腈體積比的混合溶劑的10 mmol/L乙酸銨溶液; B:乙酸銨溶於95%乙腈和5%水體積比的混合溶劑的8 mmol/L乙酸銨溶液; 進行梯度洗脫。Mobile phase: A: 10 mmol/L ammonium acetate solution in which ammonium acetate is dissolved in a mixed solvent of 95% water and 5% acetonitrile by volume; B: 8 mmol/L ammonium acetate solution in which ammonium acetate is dissolved in a mixed solvent of 95% acetonitrile and 5% water by volume; Perform gradient elution.
測試結果如下表2所示,每個樣品均進行兩次測試後取均值。
表2:不同樣品的AST-3424含量以及雜質含量表
在三種過濾膜材中,除了通過PTFE過濾的樣品之外,所有樣品在過濾之前和之後的含量測定水準保持不變。通過PTFE過濾的樣品的測定值略有增加。原因可能是由於乙醇的一些蒸發。所有樣品的雜質在試驗過濾過程中沒有顯著變化,但考慮到注射液的長期存儲,相比較而言,與其他兩種膜材相比,PVDF的濾液雜質最少。因此,根據實驗推薦將最優異的PVDF膜材用於AST-3424注射液的膠塞包裝。Among the three filtration membrane materials, except for the samples filtered through PTFE, the content determination level of all samples before and after filtration remained unchanged. The measured value of the sample filtered through PTFE increased slightly. The reason may be due to some evaporation of ethanol. The impurities of all samples did not change significantly during the test filtration process, but considering the long-term storage of the injection, compared with the other two membrane materials, the PVDF filtrate has the least impurities. Therefore, according to the experiment, it is recommended to use the most excellent PVDF membrane material for the rubber stopper packaging of AST-3424 injection.
進一步分析,比較覆膜對照組浸泡液、覆膜對照組穿刺後注射液的雜質含量,可以發現其雜質含量升高,而且在HPLC分析峰中出現了新的未在過濾膜材組對應的注射液中出現的新雜質,也就是說,AST-3424注射液極有可能會溶解覆膜對照組所使用的黏附劑。Further analysis, comparing the impurity content of the soaking solution of the film-coated control group and the injection of the film-coated control group after puncture, it can be found that the impurity content is increased, and a new injection that is not in the filter membrane material group appears in the HPLC analysis peak. The new impurities appearing in the liquid, that is, AST-3424 injection is very likely to dissolve the adhesive used in the coated control group.
由以上的對比可知,傳統的覆膜膠塞對於AST-3424注射液的包裝存在污染的風險。為此,本發明的包裝瓶的膠塞應該使用「變形壓合」的操作,而不使用任何黏合劑或其他助劑:在壓蓋膠塞時,應將圓形的膜材置於膠塞的下方,然後按照膜材在先、膠塞在上的方式進行一次壓合,利用壓合過程中膜材的變形(塑性變形和/或彈性變形)來與膠塞貼合併密封。From the above comparison, it can be seen that the traditional film-coated rubber stopper has the risk of contamination to the packaging of AST-3424 injection. For this reason, the rubber stopper of the packaging bottle of the present invention should use the "deformation pressing" operation, without using any adhesive or other additives: when the rubber stopper is capped, the round film material should be placed on the rubber stopper Then press the film material first and the rubber plug on the bottom, and use the deformation (plastic deformation and/or elastic deformation) of the film material during the pressing process to adhere and seal with the rubber plug.
在確定了上述的膜材材質後,試驗表明膜材厚度影響不大,本領域技術人員根據實際情況以及膠塞的彈性大小可以自主選擇。根據實際情況以及成本可以明確,上述試驗表明,較佳範圍的50-150微米厚度的膜材滿足要求。更厚或更薄的膜材可能會使得壓合操作困難或增加成本,過厚的膜材也存在雜質更多的風險,因此發明人根據經驗給出上述推薦值。After the above-mentioned membrane material is determined, the test shows that the thickness of the membrane material has little effect, and those skilled in the art can independently choose according to the actual situation and the elasticity of the rubber stopper. According to the actual situation and cost, it can be clear that the above test shows that the film material with a thickness of 50-150 microns in the preferred range meets the requirements. Thicker or thinner film materials may make the pressing operation difficult or increase costs, and too thick film materials also have more risks of impurities. Therefore, the inventors give the above recommended values based on experience.
為此基於以上的實驗,本發明給出以下的方案。For this reason, based on the above experiments, the present invention provides the following solutions.
一、包裝瓶 用於AST-3424注射液的包裝瓶,AST-3424注射液為實質由0.75 ml的無水乙醇和0.25 ml的無水丙二醇以及10 mg的AST-3424原料藥這樣比例的溶劑、原料藥組成的注射劑,包括: 瓶體,用於容納AST-3424注射液; 膠塞組件,用於塞入瓶體的瓶口中; 封蓋,用於設置在膠塞組件上卡合固定瓶口和膠塞組件, 其中,膠塞組件包括膠塞以及直接附著在該膠塞的朝向瓶口的暴露面上的覆著層,在該覆著層與膠塞之間無黏附劑層,該覆著層為聚四氟乙烯層、聚偏二氟乙烯層、四氟乙烯/六氟丙烯的共聚物層或至少兩種的複合層, 封蓋頂部形成缺口而使得膠塞露出,便於穿刺。1. Packaging bottle Packaging bottle for AST-3424 injection. AST-3424 injection is essentially an injection consisting of 0.75 ml of absolute ethanol, 0.25 ml of anhydrous propylene glycol, and 10 mg of AST-3424 raw materials in the ratio of solvents and raw materials. include: Bottle body, used to hold AST-3424 injection; Rubber stopper assembly, used to plug into the mouth of the bottle; The cap is used to fix the bottle mouth and the rubber stopper assembly on the rubber stopper assembly, Wherein, the rubber stopper assembly includes a rubber stopper and a coating layer directly attached to the exposed surface of the rubber stopper facing the bottle mouth. There is no adhesive layer between the coating layer and the rubber stopper, and the coating layer is polytetrafluoroethylene. Vinyl fluoride layer, polyvinylidene fluoride layer, tetrafluoroethylene/hexafluoropropylene copolymer layer or a composite layer of at least two, A gap is formed on the top of the cover to expose the rubber plug for easy puncture.
較佳的,覆著層為聚偏二氟乙烯層。Preferably, the covering layer is a polyvinylidene fluoride layer.
或者,覆著層為表內兩層的複合層,表層為聚偏二氟乙烯,內層為聚四氟乙烯層和/或四氟乙烯/六氟丙烯的共聚物層。Alternatively, the covering layer is a two-layer composite layer on the surface and the inner layer, the surface layer is polyvinylidene fluoride, and the inner layer is a polytetrafluoroethylene layer and/or a tetrafluoroethylene/hexafluoropropylene copolymer layer.
推薦的,覆著層的厚度為50-150微米。It is recommended that the thickness of the covering layer is 50-150 microns.
一般的,瓶體為玻璃藥水瓶。Generally, the bottle body is a glass potion bottle.
由於注射液在中性或弱鹼性下穩定,瓶體為中性或鹼性的硼矽玻璃瓶。Since the injection is stable under neutral or weak alkaline, the bottle body is a neutral or alkaline borosilicate glass bottle.
進一步的,由於注射液在光照情況下會發生變質降解,瓶體為不透光或透光率低的瓶體。一般選用棕色的玻璃瓶或上述的聚四氟乙烯、聚偏二氟乙烯、四氟乙烯/六氟丙烯的共聚物材質的瓶體(或其他材料的瓶體但內壁具有上述材料塗層隔離)。Further, since the injection solution will deteriorate and degrade under light conditions, the bottle body is an opaque or low light transmittance bottle body. Generally use brown glass bottles or the above-mentioned polytetrafluoroethylene, polyvinylidene fluoride, tetrafluoroethylene/hexafluoropropylene copolymer material bottle body (or other material bottle body but the inner wall has the above-mentioned material coating isolation ).
進一步,膠塞包括基體和連接在該基體上的塞體,塞體的外端面具有凹陷結構;對應的,覆著層至少結合在塞體表面,但不與凹陷結構形成的內壁貼合使得凹陷結構與覆著層之間形成封閉空腔。Further, the rubber plug includes a base body and a plug body connected to the base body. The outer end surface of the plug body has a concave structure; correspondingly, the covering layer is at least bonded to the surface of the plug body, but does not adhere to the inner wall formed by the concave structure so that A closed cavity is formed between the recessed structure and the covering layer.
推薦的,膠塞為氯化丁基橡膠塞。It is recommended that the rubber stopper is a chlorinated butyl rubber stopper.
進一步,覆著層因凹陷結構與覆著層之間形成的封閉空腔內具有的壓縮氣體的作用而形成向外的突起。Further, the covering layer forms outward protrusions due to the action of the compressed gas in the closed cavity formed between the recessed structure and the covering layer.
本發明提供的包裝瓶,由於採用特別的「變形壓合」的操作,而不使用任何黏合劑或其他助劑:在壓蓋膠塞時,應將圓形的膜材(即上述的覆著層)置於膠塞的下方,然後按照膜材在下、膠塞在上的方式進行一次壓合,利用壓合過程中膜材的變形(塑性變形和/或彈性變形)來與膠塞貼合併密封,在這個過程中,由於膠塞的凹陷結構與覆著層之間具有空腔,而在快速的壓合過程中,會將氣體(在保護氣體氣氛下壓合)壓合密封在這個空腔內使得內部壓強較外界大而形成突起的鼓包。The packaging bottle provided by the present invention does not use any adhesive or other auxiliaries due to the special "deformation pressing" operation: when pressing the rubber stopper, the round film material (that is, the above-mentioned covering Layer) is placed under the rubber stopper, and then presses the film material on the bottom and the rubber stopper on top. The deformation of the film material (plastic deformation and/or elastic deformation) during the pressing process is used to adhere to the rubber stopper. Sealing. In this process, because there is a cavity between the recessed structure of the rubber plug and the covering layer, and in the rapid pressing process, the gas (pressing under a protective gas atmosphere) is press-fitted and sealed in this cavity The cavity makes the internal pressure larger than the outside and forms a protruding bulge.
如此設計是出於兩個目的: 驗證氣密性、驗證封裝是否被破壞。由於這個突起的鼓包內封存了壓縮氣體,根據壓蓋操作中的操作壓力可以預先測定或標記(在瓶體上標記)這個鼓包向外鼓起的高度,一旦氣密性不合格或是被使用而刺破鼓包(無論是惡意還是正常被使用)都會使得這個突起的鼓包因壓縮氣體泄出而塌陷。因此通過觀察這個突起的鼓包是否塌陷,是否塌陷超過預先設置在瓶體上的標記可以驗證氣密性,驗證封裝是否被破壞,驗證是否已經被使用過。This design is for two purposes: Verify air tightness and verify whether the package is damaged. Since compressed gas is sealed in the protruding bulge, it can be pre-measured or marked (marked on the bottle body) according to the operating pressure during the capping operation. Once the airtightness fails or is used And piercing the bulge (whether maliciously or normally used) will cause the protruding bulge to collapse due to the escape of compressed gas. Therefore, by observing whether the protruding bulge collapses, whether it collapses beyond the mark set on the bottle body in advance, the air tightness can be verified, whether the package is damaged, and whether it has been used.
快速的使得注射液中蒸發的溶劑滴落到瓶體中。由於這個突起的鼓包的形狀是近乎「V」形,這樣從瓶體的注射液中蒸發而凝結的溶劑(主要是乙醇)可以通過這個鼓包被彙集到中心的最低點處,藉以更快的滴落,使得瓶體中注射液的濃度的改變可能性減小。由於AST-3424為高活性抗腫瘤藥物,而注射液在使用時是根據標識的濃度來計算抽取體積的,蒸發凝結會使得實際濃度比表示濃度高,這樣計算的抽取體積的注射液的藥物含量會比預定的量高,如此會增加用藥的風險。而使用上述的方案就能一定程度上減小這個風險。Quickly make the solvent evaporated in the injection drip into the bottle. Since the shape of the protruding bulge is almost "V" shape, the solvent (mainly ethanol) that evaporates and condenses from the injection liquid in the bottle can be collected to the lowest point of the center through this bulge, so as to drip faster. Falling, so that the possibility of changing the concentration of the injection solution in the bottle is reduced. Since AST-3424 is a highly active anti-tumor drug, and the injection volume is calculated according to the labeled concentration when using it, evaporation and condensation will make the actual concentration higher than the indicated concentration. The drug content of the injection volume calculated in this way is Will be higher than the predetermined amount, which will increase the risk of medication. The use of the above scheme can reduce this risk to a certain extent.
進一步,該包裝瓶還具有保護蓋, 保護蓋具有圓柱形蓋部分和與圓柱形蓋部分連接的圈形的收頸部分, 圓柱形蓋部分用於包覆基體,收頸部分用於套住瓶口, 保護蓋扣合且覆蓋在封蓋頂部形成的缺口而使得露出的膠塞被覆蓋。Furthermore, the packaging bottle also has a protective cover, The protective cover has a cylindrical cover part and a ring-shaped necked part connected with the cylindrical cover part, The cylindrical cap part is used to cover the substrate, and the neck part is used to cover the bottle mouth. The protective cover is buckled and covers the gap formed on the top of the cover so that the exposed rubber plug is covered.
二、藥液灌裝方法 由於本發明的膠塞和覆著層之間還設計了特別的突起鼓包結構,為此本發明實際上提供了一種對應的藥液灌裝方法。2. Liquid medicine filling method Since a special protruding bulge structure is also designed between the rubber stopper and the covering layer of the present invention, the present invention actually provides a corresponding liquid medicine filling method for this purpose.
膠塞具有突起結構的藥液包裝瓶的生產方法,其包括以下操作: 在壓蓋膠塞時,將覆著層置於膠塞的下方,然後按照覆著層在下、膠塞在上的方式進行一次壓合,利用壓合過程中膜材的變形(塑性變形和/或彈性變形)來與膠塞貼合併密封完成膠塞的壓蓋。The method for producing a liquid medicine packaging bottle with a rubber stopper having a protruding structure includes the following operations: When pressing the rubber stopper, place the covering layer under the rubber stopper, and then perform a pressing process with the covering layer on the bottom and the rubber stopper on top. The deformation of the membrane material (plastic deformation and/or plastic deformation) is used during the pressing process. Or elastic deformation) to be attached to the rubber plug and sealed to complete the gland of the rubber plug.
具體的AST-3424藥物製劑的生產操作流程圖見圖1。
步驟1:溶解與混合
步驟2-1:加乙醇溶液
用燒杯稱取處方量的AST-3424原料藥(已除熱源),投入配料罐中。加入處方量50 %的藥用無水乙醇(已除熱源)攪拌至溶解(溶解時間15 min,攪拌速度50 HZ即50轉每分鐘)。
步驟2-2:加丙二醇
加入處方量丙二醇(已除熱源),攪拌至溶解(溶解時間15 min,攪拌速度50HZ即50轉每分鐘)。
步驟2-3:混合
加入處方量50 %的藥用無水乙醇(已除熱源),攪拌至溶解(溶解時間15 min,攪拌速度50 HZ即50轉每分鐘)。
步驟3:除菌
對步驟2中得到的溶液進行除菌操作。
步驟4:無菌灌裝並加塞
進行無菌灌裝,裝量為1.0-1.2 ml (0.860-1.032 g)的上述AST-3424注射液。
在灌裝後加蓋膠塞時,將覆著層置於膠塞的下方,然後按照覆著層在下、膠塞在上的方式進行一次壓合,利用壓合過程中膜材的變形(塑性變形和/或彈性變形)來與膠塞貼合併密封完成膠塞的壓蓋。
步驟5:軋蓋和外觀檢查
灌裝好的藥瓶經輸送網帶傳至軋蓋間進行軋蓋:加壓鋁封蓋和保護蓋。
進行外觀檢查。
步驟6:放行檢驗
取樣AST-3424注射液供QC檢驗,QA放行後的供臨床使用期間在-20 ℃貯藏。The specific production flow chart of AST-3424 pharmaceutical preparations is shown in Figure 1.
Step 1: Dissolve and mix
Step 2-1: Add ethanol solution
Weigh the prescription amount of AST-3424 API (with heat source removed) in a beaker, and put it into the ingredient tank. Add 50% of the prescription amount of medicinal absolute ethanol (the heat source has been removed) and stir to dissolve (dissolving time 15 min, stirring speed 50 HZ, or 50 revolutions per minute).
Step 2-2: Add propylene glycol
Add the prescription amount of propylene glycol (the heat source has been removed), and stir until it dissolves (dissolving time 15 min, stirring speed 50HZ, namely 50 revolutions per minute).
Step 2-3: Mix
Add 50% of the prescription amount of medicinal absolute ethanol (the heat source has been removed), and stir until it dissolves (dissolving time 15 min, stirring speed 50 HZ, or 50 revolutions per minute).
Step 3: Sterilization
The solution obtained in
本發明提供的藥液灌裝方法,由於採用特別的「變形壓合」的操作,而不使用任何黏合劑或其他助劑:在壓蓋膠塞時,應將圓形的膜材(即上述的覆著層)置於膠塞的下方,然後按照膜材在下、膠塞在上的方式進行一次壓合,利用壓合過程中膜材的變形(塑性變形和/或彈性變形)來與膠塞貼合併密封,在這個過程中,由於膠塞的凹陷結構與覆著層之間具有空腔,而在快速的壓合過程中,會將氣體(在保護氣體氣氛下壓合)壓合密封在這個空腔內使得內部壓強較外界大而形成突起的鼓包。The liquid medicine filling method provided by the present invention does not use any adhesives or other auxiliaries due to the special "deformation pressing" operation: when pressing the rubber stopper, the circular membrane material (that is, the above-mentioned The covering layer) is placed under the rubber stopper, and then presses the film material down and the rubber stopper up. The deformation of the film material (plastic deformation and/or elastic deformation) during the pressing process is used to combine with the rubber The plug is attached and sealed. In this process, due to the cavity between the concave structure of the rubber plug and the covering layer, the gas (compressed under a protective gas atmosphere) will be compressed and sealed during the rapid pressing process. In this cavity, the internal pressure is greater than the outside, and a protruding bulge is formed.
如此設計是出於兩個目的: 驗證氣密性、驗證封裝是否被破壞。由於這個突起的鼓包內封存了壓縮氣體,根據壓蓋操作中的操作壓力可以預先測定或標記(在瓶體上標記)這個鼓包向外鼓起的高度,一旦氣密性不合格或是被使用而刺破鼓包(無論是惡意還是正常被使用)都會使得這個突起的鼓包因壓縮氣體泄出而塌陷。因此通過觀察這個突起的鼓包是否塌陷,是否塌陷超過預先設置在瓶體上的標記可以驗證氣密性,驗證封裝是否被破壞,驗證是否已經被使用過。This design is for two purposes: Verify air tightness and verify whether the package is damaged. Since compressed gas is sealed in the protruding bulge, it can be pre-measured or marked (marked on the bottle body) according to the operating pressure during the capping operation. Once the airtightness fails or is used And piercing the bulge (whether maliciously or normally used) will cause the protruding bulge to collapse due to the escape of compressed gas. Therefore, by observing whether the protruding bulge collapses, whether it collapses beyond the mark set on the bottle body in advance, the air tightness can be verified, whether the package is damaged, and whether it has been used.
快速的使得注射液中蒸發的溶劑滴落到瓶體中。由於這個突起的鼓包的形狀是近乎「V」形,這樣從瓶體的注射液中蒸發而凝結的溶劑(主要是乙醇)可以通過這個鼓包被彙集到中心的最低點處,藉以更快的滴落,使得瓶體中注射液的濃度的改變可能性減小。由於AST-3424為高活性抗腫瘤藥物,而注射液在使用時是根據標識的濃度來計算抽取體積的,蒸發凝結會使得實際濃度比表示濃度高,這樣計算的抽取體積的注射液的藥物含量會比預定的量高,如此會增加用藥的風險。而使用上述的方案就能一定程度上減小這個風險。Quickly make the solvent evaporated in the injection drip into the bottle. Since the shape of the protruding bulge is almost "V" shape, the solvent (mainly ethanol) that evaporates and condenses from the injection liquid in the bottle can be collected to the lowest point of the center through this bulge, so as to drip faster. Falling, so that the possibility of changing the concentration of the injection solution in the bottle is reduced. Since AST-3424 is a highly active anti-tumor drug, and the injection volume is calculated according to the labeled concentration when using it, evaporation and condensation will make the actual concentration higher than the indicated concentration. The drug content of the injection volume calculated in this way is Will be higher than the predetermined amount, which will increase the risk of medication. The use of the above scheme can reduce this risk to a certain extent.
三、膠塞具有突起結構的藥液包裝瓶3. Liquid medicine packaging bottle with rubber stopper with protruding structure
進一步,根據以上的實驗和直接將膜材覆著在膠塞上形成突起結構(鼓包)的原理和有益效果的分析,本發明還提供如下方案的膠塞具有突起結構的藥液包裝瓶。Further, based on the above experiments and the analysis of the principle and beneficial effects of directly covering the film material on the rubber stopper to form a protruding structure (bulge), the present invention also provides the following solution for the liquid medicine packaging bottle with the protruding structure of the rubber stopper.
一種膠塞具有突起結構的藥液包裝瓶,用於包裝藥液,所述藥液可以是AST-3424注射液也可以是其他藥液,其包括: 瓶體,用於容納藥液; 膠塞組件,用於塞入瓶體的瓶口中,包括膠塞以及直接附著在該膠塞的朝向瓶口的暴露面上的覆著層; 封蓋,用於設置在膠塞組件上卡合固定瓶口和膠塞組件, 其中,膠塞包括基體和連接在該基體上的塞體,塞體的外端面具有凹陷結構, 對應的,覆著層至少結合在塞體表面,但不與凹陷結構形成的內壁貼合使得凹陷結構與覆著層之間形成封閉空腔, 覆著層因凹陷結構與覆著層之間形成的封閉空腔內具有的壓縮氣體的作用而形成向外的突起或鼓包。A liquid medicine packaging bottle with a rubber stopper with a protruding structure is used for packaging liquid medicine. The liquid medicine can be AST-3424 injection or other liquid medicine, which includes: Bottle body, used to contain liquid medicine; The rubber stopper assembly is used to plug into the mouth of the bottle body, including a rubber stopper and a coating layer directly attached to the exposed surface of the rubber stopper facing the mouth of the bottle; The cap is used to fix the bottle mouth and the rubber stopper assembly on the rubber stopper assembly, Wherein, the rubber plug includes a base body and a plug body connected to the base body, and the outer end surface of the plug body has a recessed structure, Correspondingly, the covering layer is at least bonded to the surface of the plug body, but does not adhere to the inner wall formed by the recessed structure so that a closed cavity is formed between the recessed structure and the covering layer, The covering layer forms outward protrusions or bulges due to the action of the compressed gas in the enclosed cavity formed between the recessed structure and the covering layer.
顯然,膠塞為彈性材料製成,較佳為橡膠,更較佳為藥用的氯化丁基橡膠。Obviously, the rubber stopper is made of elastic material, preferably rubber, more preferably medicinal chlorinated butyl rubber.
進一步的,在該覆著層與膠塞之間無黏附劑層,該覆著層為聚四氟乙烯層、聚偏二氟乙烯層、四氟乙烯/六氟丙烯的共聚物層或至少兩種的複合層。Further, there is no adhesive layer between the covering layer and the rubber stopper, and the covering layer is a polytetrafluoroethylene layer, a polyvinylidene fluoride layer, a tetrafluoroethylene/hexafluoropropylene copolymer layer or at least two Kind of composite layer.
進一步的,覆著層為聚偏二氟乙烯層。Further, the covering layer is a polyvinylidene fluoride layer.
更加進一步的,覆著層為四氟乙烯/六氟丙烯的共聚物層。Furthermore, the coating layer is a copolymer layer of tetrafluoroethylene/hexafluoropropylene.
推薦的,覆著層的厚度為50-150微米。It is recommended that the thickness of the covering layer is 50-150 microns.
上述提供的包裝瓶的瓶體和膠塞均使用常規現有的藥水瓶和對應的膠塞在灌裝後加蓋膠塞時,將覆著層置於膠塞的下方,然後按照覆著層在下、膠塞在上的方式進行一次壓合,利用壓合過程中膜材的變形(塑性變形和/或彈性變形)來與膠塞貼合併密封完成膠塞的壓蓋。在這個過程中,由於膠塞的凹陷結構與覆著層之間具有空腔,而在快速的壓合過程中,會將氣體(在保護氣體氣氛下壓合)壓合密封在這個空腔內使得內部壓強較外界大而形成突起的鼓包。The bottle body and rubber stopper of the above-provided packaging bottle use conventional existing medicine bottle and corresponding rubber stopper. When the rubber stopper is capped after filling, the covering layer is placed under the rubber stopper, and then according to the covering layer. , The rubber plug is pressed together once, and the deformation (plastic deformation and/or elastic deformation) of the film material during the pressing process is used to adhere and seal the rubber plug to complete the gland of the rubber plug. In this process, because there is a cavity between the recessed structure of the rubber plug and the covering layer, the gas (compressed under a protective gas atmosphere) is compressed and sealed in this cavity during the rapid pressing process Make the internal pressure larger than the outside and form a protruding bulge.
如此設計是出於兩個目的: 驗證氣密性、驗證封裝是否被破壞。由於這個突起的鼓包內封存了壓縮氣體(多為惰性氣體,如氮氣),根據壓蓋操作中的操作壓力可以預先測定或標記(在瓶體上標記)這個鼓包向外鼓起的高度,一旦氣密性不合格或是被使用而刺破鼓包(無論是惡意還是正常被使用)都會使得這個突起的鼓包因壓縮氣體泄出而塌陷。因此通過觀察這個突起的鼓包是否塌陷,是否塌陷超過預先設置在瓶體上的標記可以驗證氣密性,驗證封裝是否被破壞,驗證是否已經被使用過。This design is for two purposes: Verify air tightness and verify whether the package is damaged. Since compressed gas (mostly inert gas, such as nitrogen) is sealed in the bulge of this protrusion, the height of this bulge can be pre-measured or marked (marked on the bottle body) according to the operating pressure in the capping operation. Once Unqualified air-tightness or puncture of the bulge (whether malicious or normal use) will cause the protruding bulge to collapse due to the escape of compressed gas. Therefore, by observing whether the protruding bulge collapses, whether it collapses beyond the mark set on the bottle body in advance, the air tightness can be verified, whether the package is damaged, and whether it has been used.
快速的使得注射液中蒸發的溶劑滴落到瓶體中。由於這個突起的鼓包的形狀是近乎「V」形,這樣從瓶體的注射液中蒸發而凝結的溶劑(比如揮發性的乙醇或其他含有揮發性成分的藥液)可以通過這個這個鼓包被彙集到中心的最低點處,藉以更快的滴落,使得瓶體中藥液的濃度的改變可能性減小。Quickly make the solvent evaporated in the injection drip into the bottle. Since the shape of the protruding bulge is almost "V" shape, so that the condensed solvent (such as volatile ethanol or other liquid medicine containing volatile components) that evaporates from the injection liquid in the bottle can be collected through this bulge To the lowest point in the center, it will drop faster, so that the possibility of changing the concentration of the liquid medicine in the bottle is reduced.
顯然,這樣的設計對於一些高活性抗腫瘤藥物或其他注射劑是十分重要的:這些藥液在使用時是根據標識的濃度來計算抽取體積的,蒸發凝結會使得實際濃度比表示濃度高,這樣計算的抽取體積的藥液的藥物含量會比預定的量高,如此會增加用藥的風險。而使用上述的方案就能一定程度上減小這個風險。Obviously, this design is very important for some highly active anti-tumor drugs or other injections: when these liquids are used, the extraction volume is calculated based on the labeled concentration. Evaporation and condensation will make the actual concentration higher than the indicated concentration. This calculation The drug content of the extracted volume of liquid medicine will be higher than the predetermined amount, which will increase the risk of medication. The use of the above scheme can reduce this risk to a certain extent.
進一步為了使得上述鼓包或突起的位置變化更加直觀,在瓶體(藥水瓶)的瓶身或瓶頸部分上設置的刻度線來標記突起或鼓包的設計位置。Further, in order to make the position change of the above-mentioned bulge or protrusion more intuitive, a scale line is provided on the bottle body or the neck part of the bottle body (medicine bottle) to mark the design position of the protrusion or bulge.
推薦的,上述的刻度線其實是有寬度的標記帶圈,其包括兩個刻畫圈,上圈為設計時的低溫位置,下圈為設計時的高溫位置:即根據設計該包裝瓶在容納對應的藥液後,處於設計的最低溫度時該突起或鼓包的最低點位於該低溫位置對應的上圈,處於設計的最高溫度時該突起或鼓包的最低點位於該高溫位置對應的下圈。It is recommended that the above-mentioned scale line is actually a wide marking band, which includes two engraved circles, the upper circle is the low temperature position during design, and the bottom circle is the high temperature position during design: that is, the packaging bottle is designed to accommodate the corresponding The lowest point of the protrusion or bulge is located at the upper ring corresponding to the low temperature position at the designed lowest temperature, and the lowest point of the protrusion or bulge is located at the lower ring corresponding to the high temperature position at the designed highest temperature.
而一旦氣密性不合格或是被使用而刺破鼓包(無論是惡意還是正常被使用)都會使得這個突起或鼓包因壓縮氣體泄出而塌陷,此時突起或鼓包必定位於上述的低溫位置對應的上圈之上(對應氣密性不合格)或直接消失(對應被使用而刺破鼓包)。Once the air tightness is unqualified or the bulge is pierced by use (either maliciously or normally), the protrusion or bulge will collapse due to the release of compressed gas. At this time, the protrusion or bulge must be positioned at the above-mentioned low temperature position. Above the upper circle (corresponding to unqualified air tightness) or disappear directly (corresponding to being used and piercing the bulge).
四、包裝套件 一種用於AST-3424注射液的包裝套件,包括: 包裝盒; 氣體保護袋,其內填充有大於大氣壓的保護氣體,被設置在包裝盒中; 包裝瓶,被封裝在氣體保護袋中; 其中,包裝瓶為上述的用於AST-3424注射液的包裝瓶。 作為一種進一步的保護,氣體保護袋填充氣體為氮氣,氣體保護袋的材質為鋁塑雙層複合材料。Four, packaging kit A packaging kit for AST-3424 injection, including: Packing box A gas protection bag, which is filled with a protection gas greater than atmospheric pressure, is set in the packaging box; The packaging bottle is enclosed in a gas protective bag; Among them, the packaging bottle is the aforementioned packaging bottle for AST-3424 injection. As a further protection, the gas protection bag is filled with nitrogen gas, and the material of the gas protection bag is aluminum-plastic double-layer composite material.
一般的,包裝瓶為2/5/10毫升規格的棕色避光玻璃藥水瓶。Generally, the packaging bottle is a brown, light-proof glass syrup bottle of 2/5/10 ml specification.
本發明提供一種具有突起的藥液包裝瓶的灌注加塞壓蓋裝置,其一體化的完成藥液的灌注、加塞以及壓蓋,因此所得到的包裝瓶能解決上述兩個問題。The present invention provides a filling, stoppering and capping device for a medicinal solution packaging bottle with protrusions, which integrally completes the filling, stoppering and capping of the medicinal solution, so the obtained packaging bottle can solve the above two problems.
傳統的覆膜膠塞是直接塞入到瓶口的,本發明的包裝瓶的膠塞使用「變形壓合」的操作,使用或不使用任何黏合劑或其他助劑:在壓蓋膠塞時,將彈性的覆著層(膜材)置於膠塞的下方,然後將覆著層(膜材)先進行預壓後得到突起的結構,再壓上膠塞,利用壓合過程中膜材的變形(塑性變形和/或彈性變形)來與膠塞貼合併密封,利用壓合過程中覆著層(膜材)的再次變形(塑性變形和/或彈性變形)來與膠塞貼合併密封完成膠塞的壓蓋。在這個過程中,由於膠塞的凹陷結構與覆著層之間具有空腔,而在快速的壓合過程中,會將氣體(在保護氣體氣氛下壓合)壓合密封在這個空腔與上述覆著層形成的突起結構內使得內部壓強較外界大而形成更加明顯的突起或鼓包。The traditional film-coated rubber stopper is directly inserted into the bottle mouth. The rubber stopper of the packaging bottle of the present invention uses the "deformation pressing" operation, with or without any adhesive or other additives: when the rubber stopper is capped , Place the elastic covering layer (membrane material) under the rubber stopper, and then pre-press the covering layer (membrane material) to obtain a protruding structure, and then press the rubber stopper, using the membrane material in the pressing process The deformation (plastic deformation and/or elastic deformation) of the rubber plug is attached and sealed, and the re-deformation (plastic deformation and/or elastic deformation) of the covering layer (film material) during the pressing process is used to adhere and seal the rubber plug Complete the gland of the rubber stopper. In this process, because there is a cavity between the recessed structure of the rubber plug and the covering layer, and in the rapid pressing process, the gas (pressing under a protective gas atmosphere) is pressed and sealed in this cavity and In the protrusion structure formed by the coating layer, the internal pressure is larger than the outside, and more obvious protrusions or bulges are formed.
同樣設計突起或鼓包是出於兩個目的:The same design of protrusions or bulges is for two purposes:
驗證氣密性、驗證封裝是否被破壞。由於這個突起的鼓包內封存了壓縮氣體,根據壓蓋操作中的操作壓力可以預先測定或標記(在瓶體上標記)這個鼓包向外鼓起的高度,一旦氣密性不合格或是被使用而刺破鼓包(無論是惡意還是正常被使用)都會使得這個突起的鼓包因壓縮氣體泄出而塌陷。因此通過觀察這個突起的鼓包是否塌陷,是否塌陷超過預先設置在瓶體上的標記可以驗證氣密性,驗證封裝是否被破壞,驗證是否已經被使用過。Verify air tightness and verify whether the package is damaged. Since compressed gas is sealed in the protruding bulge, it can be pre-measured or marked (marked on the bottle body) according to the operating pressure during the capping operation. Once the airtightness fails or is used And piercing the bulge (whether maliciously or normally used) will cause the protruding bulge to collapse due to the escape of compressed gas. Therefore, by observing whether the protruding bulge collapses, whether it collapses beyond the mark set on the bottle body in advance, the air tightness can be verified, whether the package is damaged, and whether it has been used.
快速地使注射液中蒸發的溶劑滴落到瓶體中。由於這個突起的鼓包的形狀是近乎「V」形,這樣從瓶體的注射液中蒸發而凝結的溶劑(比如揮發性的乙醇或其他含有揮發性成分的藥液)可以通過這個鼓包被彙集到中心的最低點處,藉以更快的滴落,使得瓶體中藥液的濃度的改變可能性減小。Quickly make the solvent evaporated in the injection drop into the bottle. Since the shape of the protruding bulge is almost "V" shape, the solvent (such as volatile ethanol or other liquid medicine containing volatile components) that evaporates and condenses from the injection liquid in the bottle can be collected through this bulge At the lowest point in the center, the faster dripping reduces the possibility of changing the concentration of the liquid medicine in the bottle.
本發明提供的灌注加塞壓蓋裝置通過先將覆著層預壓在藥水瓶瓶口上形成突起,然後再加塞、壓蓋完成灌封工作,通過預壓可以使得形成的突起更明顯,藉以更好的達到上述效果,肉眼觀察的對比也更方便、快捷。The perfusion, stoppering and capping device provided by the present invention firstly pre-presses the coating layer on the mouth of the medicine bottle to form protrusions, and then plugs and caps to complete the filling and sealing work. The pre-compression can make the formed protrusions more obvious, which is better To achieve the above effects, the comparison with naked eyes is also more convenient and faster.
基於以上的發明思路,本發明提供以下的實驗方案。 五、灌注加塞壓蓋裝置 具有突起的藥液包裝瓶的灌注加塞壓蓋裝置,包括: 輸送機構,用於夾持固定藥水瓶並移動到不同位置; 灌液機構,包括灌液針頭和藥液定量開關,與儲液箱連接,用於定量將藥液注入到處於灌液位置的空藥水瓶中; 送料機構,用於輸送並將覆著層放置在預壓位置的灌注有藥液的藥水瓶的瓶口上; 覆著層預壓機構,包括驅動元件以及與該驅動元件連接的預壓模,用於將放置在處於預壓位置的藥水瓶瓶口上的覆著層預壓成向下具有弧形突起的形狀; 加塞機構,用於將膠塞壓入到預壓了覆著層的處於加塞位置的藥水瓶的瓶口上;以及 壓蓋機構,用於將鋁蓋軋到加塞了的處於壓蓋位置的藥水瓶的瓶口上。Based on the above inventive idea, the present invention provides the following experimental scheme. Five, filling, plugging and capping device The filling, stoppering and capping device for a liquid medicine packaging bottle with protrusions includes: Conveying mechanism, used to clamp the fixed medicine bottle and move it to different positions; The filling mechanism, including the filling needle and the liquid medicine metering switch, is connected with the liquid storage tank, and is used for quantitatively injecting the medicine liquid into the empty medicine water bottle in the filling position; Feeding mechanism for conveying and placing the covering layer on the mouth of the liquid medicine bottle filled with liquid medicine at the pre-pressing position; The coating pre-pressing mechanism includes a driving element and a pre-compression die connected with the driving element, which is used to pre-press the coating layer placed on the mouth of the medicine bottle in the pre-pressing position into a shape with an arc-shaped protrusion downward ; The stopper mechanism is used to press the rubber stopper into the mouth of the medicine bottle in the stoppered position with the coating layer pre-compressed; and The capping mechanism is used to roll the aluminum cap onto the stopper of the medicine bottle in the capping position.
輸送機構的目的就是將空的藥水瓶一個一個有序的輸送到預定的位置上。The purpose of the conveying mechanism is to orderly convey the empty medicine bottles to the predetermined position one by one.
通常的,輸送機構有兩類:圓盤式旋轉輸送機構或直線式輸送機構。Generally, there are two types of conveying mechanisms: disc type rotary conveying mechanism or linear conveying mechanism.
圓盤式輸送機構,基本原理就是設置主轉盤,並在主轉盤的四周設置與藥水瓶相匹配的卡盤,通過匹配的理瓶機將一個個藥水瓶卡入卡盤的卡口中,在旋轉中將藥水瓶輸送到預定的位置上。這類機構比較常用,比如中國專利文獻CN206544899U中揭露的一種雙位置藥水瓶灌裝機 、CN206172956U中揭露的液體灌裝加塞機、CN203558514U中揭露的灌裝加塞機理瓶裝置、CN207015615U中揭露的灌裝封口機、CN1431141A中揭露的高速液體灌裝加塞機均使用這種圓盤式輸送機構進行藥水瓶的輸送。The basic principle of the disc type conveying mechanism is to set the main turntable, and set up the chuck matching the medicine bottle around the main turntable, and use the matching bottle unscrambler to clip each medicine bottle into the bayonet of the chuck. The medicine bottle is transported to the predetermined position during the rotation. Such mechanisms are more commonly used, such as a dual-position medicine bottle filling machine disclosed in Chinese Patent Document CN206544899U, a liquid filling and stoppering machine disclosed in CN206172956U, a filling and corking mechanism bottle device disclosed in CN203558514U, and a filling and sealing opening disclosed in CN207015615U The high-speed liquid filling and stoppering machine disclosed in CN1431141A uses this disc conveying mechanism to convey the medicine bottle.
直線式輸送機構,與上述的圓盤式類似,只是在傳送帶上設置了具有卡口的結構,通過輸送帶的運動(間歇或連續運動)將藥水瓶輸送到預定的位置。The linear conveying mechanism is similar to the above-mentioned disc type, except that a structure with a bayonet is set on the conveyor belt, and the medicine bottle is conveyed to a predetermined position through the movement of the conveyor belt (intermittent or continuous movement).
灌液機構,為常用的注入式灌注結構,通過氣缸、致動器等驅動灌液針頭插入到瓶口中,進行灌注。在灌液針頭的管路上連接有定量的開關,保證每次灌注的量都是預定的量。The filling mechanism is a commonly used injection type filling structure, and the filling needle is driven into the bottle mouth by a cylinder, an actuator, etc., for filling. A quantitative switch is connected to the pipeline of the perfusion needle to ensure that the amount of perfusion is a predetermined amount each time.
送料機構,用於輸送並將覆著層放置在預壓位置的灌注有藥液的藥水瓶的瓶口上。一般而言,在製劑包裝機械中,送料的方式比較多,可以通過氣缸、致動器、電磁鐵、機械手等進行送料。而本發明中,由於要輸送的是覆著層,因此考慮的方案是在簡單的機械手上安裝吸盤,通過吸盤吸取覆著層後依靠機械手將覆著層轉運到藥水瓶的瓶口上。The feeding mechanism is used for conveying and placing the covering layer on the mouth of the liquid medicine bottle filled with the liquid medicine in the pre-pressing position. Generally speaking, in preparation packaging machinery, there are many ways of feeding materials, which can be fed by air cylinders, actuators, electromagnets, manipulators, etc. In the present invention, since the coating layer is to be transported, the solution considered is to install a suction cup on a simple manipulator, and then transfer the coating layer to the mouth of the medicine bottle by the manipulator after sucking the coating layer through the suction cup.
加塞機構、壓蓋機構使用的是現有的結構,CN206172956U中揭露的液體灌裝加塞機、CN207015615U中揭露的灌裝封口機、CN1431141A中揭露的高速液體灌裝加塞機均揭露了相應的結構和方案。一般而言,加塞機構就是將理好塞(可以通過螺旋振動理塞機將橡膠塞統一整理為小頭朝下)的橡膠塞塞入到藥水瓶的瓶口中,驅動結構一般為氣缸。壓蓋機構是將鋁蓋直接壓到塞了膠塞的瓶口上,然後收緊鋁蓋的下端使得下端縮小變形而將膠塞牢固地固定在瓶口中。The stoppering mechanism and the capping mechanism use the existing structure. The liquid filling and sealing machine disclosed in CN206172956U, the filling and sealing machine disclosed in CN207015615U, and the high-speed liquid filling and sealing machine disclosed in CN1431141A all disclose the corresponding structures and solutions. . Generally speaking, the stopper mechanism is to insert the rubber stopper with the correct stopper (the rubber stopper can be uniformly arranged with the small head down by the spiral vibration stopper machine) into the mouth of the medicine bottle, and the driving structure is generally an air cylinder. The capping mechanism is to directly press the aluminum cap onto the bottle mouth plugged with the rubber stopper, and then tighten the lower end of the aluminum cap so that the lower end shrinks and deforms and the rubber stopper is firmly fixed in the bottle mouth.
覆著層預壓機構,就是通過預壓模將覆著層進行預壓,得到初步的突起形狀。The covering layer pre-pressing mechanism is to pre-press the covering layer through a pre-pressing die to obtain a preliminary protrusion shape.
進一步,還包括高壓氣體吹入機構,其包括: 支撐杆,固定在加塞位置上; 吹氣環,為空心的圓環,其內壁具有出氣孔,通過管路和高壓氣源連通,內徑大於或等於所述藥水瓶的瓶口而位於瓶口上, 當預壓了覆著層的藥水瓶被所述輸送機構輸送到處於加塞位置時,所述吹氣環即剛好處於瓶口上並進行吹氣, 在所述吹氣環朝具有弧形突起形狀的所述覆著層吹送高壓氣體時,所述加塞機構將所述加塞壓入瓶口。Further, it also includes a high-pressure gas blowing mechanism, which includes: Support rod, fixed at the stopper position; The blowing ring is a hollow ring with an air outlet on its inner wall, which is connected to a high-pressure gas source through a pipeline, and has an inner diameter greater than or equal to the mouth of the medicine bottle and is located on the mouth of the bottle, When the pre-compressed medicine bottle with the coating layer is transported to the stoppered position by the conveying mechanism, the blowing ring is just right on the bottle mouth and blowing, When the blowing ring blows high-pressure gas toward the coating layer having the arc-shaped protrusion shape, the plugging mechanism presses the plugging into the bottle mouth.
這樣通過進一步設計高壓氣體吹入機構,可以在預壓後,加塞前向突起結構中吹入高壓氣體,這樣在加塞時,可以使得突起中的氣壓更大,對應的突起程度也更明顯,藉以達到更直觀的效果。In this way, by further designing the high-pressure gas blowing mechanism, it is possible to blow high-pressure gas into the protrusion structure before plugging after pre-pressing, so that when plugging, the air pressure in the protrusion can be made larger, and the corresponding protrusion degree is more obvious. Achieve a more intuitive effect.
進一步,所述出氣孔是斜向下設置的,傾斜設置可以更好的讓氣體吹入到瓶口。Further, the air outlet is arranged obliquely downward, and the oblique arrangement can better allow the gas to be blown into the bottle mouth.
進一步,所述支撐杆是中空的管狀,起到管路的作用,一端與所述高壓氣源連通,另一端與所述吹氣環連通。Further, the support rod is a hollow tube and functions as a pipeline. One end is connected with the high-pressure gas source, and the other end is connected with the blowing ring.
進一步,所述預壓模包括壓環以及套裝在該壓環內的陽模, 所述陽模上端與第一驅動元件連接,所述壓環與第二驅動元件連接, 所述陽模可在所述壓環內上下滑動,其下端為凸起的弧面, 當藥水瓶被輸送到處於預壓位置時,所述第二驅動元件驅動所述壓環將放置在瓶口上的所述覆著層的邊緣壓緊固定在瓶口上,所述第一驅動元件驅動所述陽模穿過所述壓環下壓,將所述覆著層預壓成向下具有弧形突起的形狀。Further, the pre-compression mold includes a pressure ring and a male mold sleeved in the pressure ring, The upper end of the male mold is connected with the first driving element, and the pressing ring is connected with the second driving element, The male mold can slide up and down in the pressure ring, and its lower end is a convex arc surface, When the medicine bottle is transported to the pre-pressing position, the second driving element drives the pressing ring to press and fix the edge of the coating layer placed on the bottle mouth on the bottle mouth, and the first driving element drives The male mold is pressed down through the pressing ring, and the covering layer is pre-pressed into a shape having an arc-shaped protrusion downward.
進一步,所述壓環的地面設置有緩衝用的橡膠墊圈。增加橡膠墊圈可以將覆著層壓緊同時也不會因為預壓模的下壓力過大、過快而將覆著層拉破或是撕裂。Further, the ground of the pressure ring is provided with a rubber gasket for buffering. The addition of rubber gaskets can tightly laminate the overlay while not pulling or tearing the overlay due to excessive or fast downforce of the pre-compression mold.
推薦的,所述第一驅動元件、所述第二驅動元件為氣缸或致動器或電磁鐵。Preferably, the first driving element and the second driving element are cylinders or actuators or electromagnets.
作為一種選擇,所述輸送機構為圓盤式旋轉輸送機構或直線式輸送機構。當然也可以採用螺旋杆式的輸送機構。As an option, the conveying mechanism is a disk-type rotary conveying mechanism or a linear conveying mechanism. Of course, a screw-type conveying mechanism can also be used.
六、AST-3424注射液的灌注加塞壓蓋裝置6. Perfusion, stoppering and capping device for AST-3424 injection
AST-3424 ((R)-1-(3-(3-(dimethylcarbamoyl)phenoxy)-4-nitrophenyl)ethyl di(aziridin-1-yl)phosphinate)注射液的灌注加塞壓蓋裝置,包括上述的具有突起的藥液包裝瓶的灌注加塞壓蓋裝置以及儲液箱和該儲液箱連通的灌液管路, 其中,所述儲液箱、所述灌液管路、所述灌液針頭均為316號不鏽鋼部件;或 所述儲液箱、所述灌液管路、所述灌液針頭的接觸藥液的內層均為聚偏氟乙烯層。AST-3424 ((R)-1-(3-(3-(dimethylcarbamoyl)phenoxy)-4-nitrophenyl)ethyl di(aziridin-1-yl)phosphinate) injection perfusion and stopper capping device, including the above The protruding liquid medicine packaging bottle filling, plugging and capping device and the liquid storage tank and the liquid filling pipeline connected with the liquid storage tank, Wherein, the liquid storage tank, the liquid filling pipe, and the liquid filling needle are all 316 stainless steel parts; or The inner layer of the liquid storage tank, the irrigation pipe, and the liquid injection needle contacting the liquid medicine are all polyvinylidene fluoride layers.
進一步,所述覆著層為聚偏氟乙烯層,所述送料機構均為316號不鏽鋼部件;或所述送料機構接觸藥液的部件均塗覆有為聚偏氟乙烯層。Further, the covering layer is a polyvinylidene fluoride layer, and the feeding mechanism is made of 316 stainless steel parts; or the parts of the feeding mechanism contacting the chemical liquid are all coated with a polyvinylidene fluoride layer.
之所以特別要求適用於AST-3424注射液的灌注加塞壓蓋裝置的一些直接接觸或有可能接觸藥液的部件使用316號不鏽鋼或聚偏氟乙烯層是因為經過實驗對比驗證了AST-3424藥液與這兩種材料接觸(8小時甚至24小時)不會發生反應而產生雜質,即實驗證實了這兩種材質對於AST-3424藥液而言是穩定的。The reason why it is specifically required that some parts of the infusion, stoppering and capping device suitable for AST-3424 injection are directly in contact or may be in contact with the chemical liquid to use 316 stainless steel or polyvinylidene fluoride layer because the AST-3424 drug has been verified by comparison and experiment. Liquid contact with these two materials (8 hours or even 24 hours) will not react and produce impurities, that is, experiments have confirmed that these two materials are stable for AST-3424 liquid.
七、藥水瓶的灌注加塞壓蓋方法Seven, the method of filling, stoppering and capping of the medicine bottle
本發明還提供一種藥水瓶的灌注加塞壓蓋方法,其包括覆著層預壓步驟: 在藥液灌注到藥水瓶後,對覆著層進行預壓成型使得覆著層貼附在藥水瓶瓶口並形成向瓶口內突起的結構。The present invention also provides a method for filling, stoppering and capping of a medicinal water bottle, which includes the step of pre-pressing the coating layer: After the medicinal solution is poured into the medicinal water bottle, the coating layer is pre-compressed to make the coating layer adhere to the mouth of the medicine bottle and form a structure protruding into the mouth of the bottle.
一般,藥水瓶的灌注加塞壓蓋方法主要包括灌液步驟、加塞步驟和壓蓋(軋蓋)步驟,上述的覆著層預壓步驟就是在灌液步驟後以及加塞步驟前將覆著層進行預壓而形成突起結構。Generally, the method of filling, stoppering and capping of the medicine bottle mainly includes the filling step, the stoppering step and the capping (capping) step. The above-mentioned coating pre-compression step is to carry out the coating after the filling step and before the stoppering step. Pre-compression to form a protruding structure.
進一步的,加塞步驟時將膠塞快速的壓入貼附了覆著層的瓶口。這裡的快速是為了儘快的將突起結構中的氣體(保護氣體,比如氮氣)通過膠塞快速壓入到瓶口中,使得突起結構鼓起。Further, during the stoppering step, the rubber stopper is quickly pressed into the bottle mouth to which the coating layer is attached. The quick here is to quickly press the gas (protective gas, such as nitrogen) in the protruding structure into the bottle mouth through the rubber stopper to make the protruding structure bulge.
進一步的,在進行覆著層預壓時,將放置在瓶口上的覆著層固定後使用陽模預壓。Further, when the coating layer is pre-pressed, the coating layer placed on the bottle mouth is fixed and then pre-pressed with a male mold.
具體實施例1Specific Example 1
用於AST-3424注射液的包裝瓶100,AST-3424注射液為實質由0.75 ml的無水乙醇和0.25 ml的無水丙二醇以及10 mg的AST-3424原料藥這樣比例的溶劑、原料藥組成的注射劑,包瓶體10、膠塞組件20和封蓋30。
如圖2所示,瓶體10用於容納藥液,其包括瓶身11與瓶身11連接的瓶頸12,在瓶頸的開口設置有瓶口13。As shown in FIG. 2, the
根據實際需求,瓶體10的形狀是可選的,通常為圓柱形或長方形。而且,通常瓶頸12要小於瓶身11,具體形狀如圖2所示。According to actual needs, the shape of the
如圖3所示,膠塞組件20用於塞入瓶體10的瓶口11中,包括膠塞21以及直接附著在該膠塞21的朝向瓶口13的暴露面上的覆著層22,在該覆著層22與膠塞21之間無黏附劑層,該覆著層22為聚四氟乙烯層、聚偏二氟乙烯層、四氟乙烯/六氟丙烯的共聚物層或至少前述兩種的複合層。As shown in FIG. 3, the
正如發明內容部分所公開的,具有黏附劑的黏附覆膜的膠塞21會給本發明的AST-3424帶來污染的風險,而單獨使用聚醚碸樹脂PES、聚四氟乙烯PTFE、聚偏二氟乙烯PVDF、四氟乙烯/六氟丙烯的共聚物FEP膜材製備得到覆著層22後,注射液的雜質得到改善。經過比較,聚四氟乙烯層、聚偏二氟乙烯層、四氟乙烯/六氟丙烯的共聚物層符合要求,那麼顯然這三種材料的兩兩混合或三種混合後的材料的膜材也符合隔離乙醇/丙二醇溶劑的AST-3424注射液的包裝瓶,以保證注射液與包裝瓶塞(膠塞21)之間無污染的穩定性(即不會因為注射液和覆著層接觸而使得雜質增多或出現新的雜質)要求。As disclosed in the Summary of the Invention, the
膠塞21為由彈性材質製作。The
封蓋30用於設置在膠塞組件20上卡合固定瓶口13和膠塞組件20。如圖2所示,封蓋30就是一個環形的圈,其上端套在膠塞組件20上,同時下端卡住瓶頸12。瓶頸12上有一圈凹陷122,用於讓封蓋30的下端與其卡合勾住固定,使得膠塞組件20能夠牢固的塞入固定在瓶口13中。封蓋30一般為鋁材製作。The
封蓋30頂部形成缺口31(圓形的洞)而使得膠塞21露出,便於穿刺。A gap 31 (a circular hole) is formed on the top of the
具體實施例2Specific Example 2
進一步的,在具體實施例1的包裝瓶100基礎上,覆著層22為聚偏二氟乙烯層。Further, on the basis of the
具體實施例3Specific Example 3
進一步的,在具體實施例1和/或2的包裝瓶100基礎上,覆著層22為表內兩層的複合層,表層為聚偏二氟乙烯,內層為聚四氟乙烯層和/或四氟乙烯/六氟丙烯的共聚物層。Further, on the basis of the
具體實施例4Specific Example 4
進一步的,在具體實施例1和/或2和/或3的包裝瓶100基礎上,覆著層22的厚度為50-150微米。Further, on the basis of the
具體實施例5Specific Example 5
在具體實施例1和/或2和/或3和/或4的包裝瓶100基礎上,瓶體10為玻璃藥水瓶。Based on the
玻璃藥水瓶(penicillin vial)的類型可以是管製玻璃藥水瓶,或者是模制玻璃藥水瓶,推薦使用管製玻璃藥水瓶。The type of penicillin vial can be a regulated glass potion bottle or a molded glass potion bottle. It is recommended to use a regulated glass potion bottle.
具體實施例6Specific Example 6
在具體實施例1和/或2和/或3和/或4和/或5的包裝瓶的基礎上,瓶體10為中性或鹼性的硼矽玻璃瓶。Based on the packaging bottles of
具體實施例7Specific Example 7
在具體實施例1和/或2和/或3和/或4和/或5和/或6的包裝瓶的基礎上,瓶體10為不透光或透光率低的瓶體。推薦使用棕色瓶。Based on the packaging bottles of specific examples 1 and/or 2 and/or 3 and/or 4 and/or 5 and/or 6, the
具體實施例8Specific Example 8
如圖4/5所示,在具體實施例1和/或2和/或3和/或4和/或5和/或6和/或7的包裝瓶的基礎上,膠塞21包括基體211和連接在該基體211上的塞體212,塞體212的外端面具有凹陷結構213。As shown in Figure 4/5, on the basis of the packaging bottles of
對應的,覆著層22至少結合在塞體212表面,但不與凹陷結構213形成的內壁貼合,如此將使得凹陷結構213與覆著層22之間形成封閉空腔214。Correspondingly, the covering
具體實施例9Specific Example 9
在具體實施例1和/或2和/或3和/或4和/或5和/或6和/或7和/或8的包裝瓶的基礎上,膠塞21為氯化丁基橡膠塞。On the basis of the packaging bottles of
具體實施例10Specific Example 10
如圖4/5所示,在具體實施例8和/或9的包裝瓶的基礎上,覆著層22因凹陷結構213與覆著層22之間形成的封閉空腔214內具有的壓縮氣體的作用而形成向外的鼓包或突起225。As shown in Figure 4/5, on the basis of the packaging bottles of specific embodiments 8 and/or 9, the
具體實施例11
如圖4/5所示,在具體實施例1和/或2和/或3和/或4和/或5和/或6和/或7和/或8和/或9和/或10的包裝瓶的基礎上,還包括保護蓋40,保護蓋40具有圓柱形蓋部分41和與圓柱形蓋部分41連接的圈形的收頸部分42,圓柱形蓋部分41用於包覆基體211,收頸部分42用於套住瓶口13。Specific Example 11
As shown in Figure 4/5, in
保護蓋40扣合且覆蓋在封蓋30頂部形成的缺口31(圓形的洞)而使得露出的膠塞21被覆蓋。The
具體實施例13Specific Example 13
如同發明內容所啟發的,進為了使得上述鼓包或突起225 (參照圖5)的位置變化更加直觀,在瓶體(藥水瓶)的瓶身11或瓶頸12部分上設置刻度線來標記突起或鼓包的設計位置。如圖4所示,該刻度線121就是一個寬為1.5 mm的磨砂環帶,且該環帶是間隔磨砂的,這樣便於觀察比對突起或鼓包的位置。As inspired by the content of the invention, in order to make the position change of the above-mentioned bulge or protrusion 225 (refer to FIG. 5) more intuitive, a scale line is set on the
具體實施例14-1Specific embodiment 14-1
以下實施例通過圖6來說明特別的「變形壓合」的操作。The following embodiment uses FIG. 6 to illustrate the special "deformation pressing" operation.
瓶體10和膠塞21均使用常規現有的藥水瓶和對應的膠塞21在灌裝後加蓋膠塞21時,將覆著層22置於膠塞21的下方,如圖6的左圖。Both the
然後按照覆著層22在下、膠塞21在上的方式進行一次壓合,利用壓合過程中膜材(覆著層)的變形(塑性變形和/或彈性變形)來與膠塞貼合併密封完成膠塞的壓蓋,如圖6的中圖。Then perform a pressing process with the
在這個壓合過程中,由於膠塞21的凹陷結構213與覆著層22之間具有空腔,而在快速的壓合過程中,會將氣體(在保護氣體氣氛下壓合)壓合密封在這個空腔內使得內部壓強較外界大而形成突起(鼓包)225 (請參照圖5),然後同時加壓封蓋30和保護蓋40,完成固定和密封,如圖6的右圖。In this pressing process, since there is a cavity between the recessed
具體實施例14-2Specific embodiment 14-2
請參照圖7,一種用於AST-3424注射液的包裝套件1000,包括包裝盒1002、氣體保護袋1003、包裝瓶100。Please refer to FIG. 7, a
多個氣體保護袋1003相互連接在一起。A plurality of
具體實施例15Specific Example 15
在具體實施例14的包裝套件基礎上,氣體保護袋1003填充氣體為氮氣,氣體保護袋的材質為鋁塑雙層複合材料。鋁塑雙層複合材料材質的氣體保護袋的避光性能更好。Based on the packaging kit of specific embodiment 14, the
具體實施例16Specific Example 16
在具體實施例14和/或15的包裝套件,其中,包裝瓶100為2/5/10毫升規格的棕色避光玻璃藥水瓶。In the packaging kit of specific embodiment 14 and/or 15, the
具體實施例17Specific Example 17
此實施例為變形擴展實施例。This embodiment is a modified and expanded embodiment.
以上實施例中,瓶體的材質為玻璃瓶,也可以為其他材質的藥水瓶,進一步的,可以在其他材質或玻璃材質的藥水瓶的內壁塗覆覆著層22,而該覆著層為聚四氟乙烯層、聚偏二氟乙烯層、四氟乙烯/六氟丙烯的共聚物層或至少兩種的複合層,較佳為聚偏二氟乙烯層。In the above embodiments, the material of the bottle body is a glass bottle, or a potion bottle of other materials. Further, the inner wall of a potion bottle made of other materials or glass may be coated with the
以上實施例給出了具有突起的藥液包裝瓶的結構,以下實施例具體說明本發明提供的具有突起的藥液包裝瓶的灌注加塞壓蓋裝置的具體結構。The above embodiments give the structure of a liquid medicine packaging bottle with protrusions, and the following embodiments specifically illustrate the specific structure of the filling, plugging and capping device for a liquid medicine packaging bottle with protrusions provided by the present invention.
具體實施例18Specific Example 18
如圖10所示,具有突起的藥液包裝瓶的灌注加塞壓蓋裝置1500,包括:輸送機構200,用於夾持固定藥水瓶並移動到不同位置。本實施例選用結構比較緊湊的圓盤式輸送機構,基本原理就是設置主轉盤210,並在主轉盤的四周設置與藥水瓶相匹配的卡盤220,通過匹配的理瓶機LB將一個個藥水瓶卡入卡盤220的卡口221中,在旋轉中將藥水瓶輸送到預定的位置上。對應的,這裡的預定位置也是依照圓周設置的。當然,根據每個位置上設置的對應動作機構的不同,輸送機構10對應的驅動機(步進電機)所驅動轉過的卡口數也不同,簡單的,比如一個卡盤220上設置有60個卡口,則每個對應的卡口對應的角度為6度,如果一個位置上設置10個灌液機構300、送料機構400、覆著層預壓機構500、加塞機構600、壓蓋機構700同時進行對應的操作,那麼每次驅動機驅動轉盤210旋轉60度;如果一個位置設置5個上述的各種機構,則每次驅動機驅動轉盤210旋轉30度,以此類推。本實施例中一個卡盤220上設置有30個卡口221,則每個對應的卡口對應的角度為12度,一個位置上設置1個灌液機構300、送料機構400、覆著層預壓機構500、加塞機構600、壓蓋機構700同時進行對應的操作,那麼每次驅動機驅動轉盤210旋轉12度。As shown in FIG. 10, the filling, stoppering and
請參照圖11,灌液機構300包括灌液針頭310和藥液定量開關320,與儲液箱C連接,用於定量將藥液注入到處於灌液位置的空藥水瓶中。本實施例中使用的就是常規的結構方案,如圖11所示:儲存有注射液的儲液箱C中的藥液在泵和藥液定量開關320的作用下,被定量的通過灌液針頭310注入到空的藥水瓶中。11, the
請參照圖10,送料機構400用於輸送並將覆著層放置在預壓位置的灌注有藥液的藥水瓶的瓶口上。本實施例送料機構由於要輸送的是覆著層,因此考慮的方案是在簡單的機械手上安裝吸盤,通過吸盤吸取覆著層後依靠機械手將覆著層轉運到藥水瓶的瓶口上。Please refer to FIG. 10, the
請參照圖13,覆著層預壓機構500,包括驅動元件510以及與該驅動元件連接的預壓模520,用於將放置在處於預壓位置的藥水瓶瓶口上的覆著層22預壓成向下具有弧形突起的形狀。Please refer to FIG. 13, the
請參照圖10,加塞機構600,用於將膠塞壓入到預壓了覆著層的處於加塞位置的藥水瓶的瓶口上。Please refer to FIG. 10, the
壓蓋機構700,用於將鋁蓋軋到加塞了的處於壓蓋位置的藥水瓶的瓶口上。The
加塞機構、壓蓋機構使用的是現有市面上供應的結構,CN206172956U中揭露的液體灌裝加塞機、CN207015615U中揭露的灌裝封口機、CN1431141A中揭露的高速液體灌裝加塞機均揭露了相應的結構和方案。一般而言,加塞機構就是將理好塞(可以通過螺旋振動理塞機將橡膠塞統一整理為小頭朝下)的橡膠塞塞入到藥水瓶的瓶口中,驅動結構一般為氣缸。壓蓋機構是將鋁蓋直接壓到塞了膠塞的瓶口上,然後收緊鋁蓋的下端使得下端縮小變形而將膠塞牢固地固定在瓶口。The stoppering mechanism and the capping mechanism use the existing market-supplied structures. The liquid filling and sealing machine disclosed in CN206172956U, the filling and sealing machine disclosed in CN207015615U, and the high-speed liquid filling and sealing machine disclosed in CN1431141A all disclose the corresponding Structure and plan. Generally speaking, the stopper mechanism is to insert the rubber stopper with the correct stopper (the rubber stopper can be uniformly arranged with the small head down by the spiral vibration stopper machine) into the mouth of the medicine bottle, and the driving structure is generally an air cylinder. The capping mechanism directly presses the aluminum cap onto the bottle mouth plugged with the rubber stopper, and then tightens the lower end of the aluminum cap so that the lower end shrinks and deforms to firmly fix the rubber stopper on the bottle mouth.
具體實施例19Specific Example 19
在上述實施例4的基礎上,如圖10/12所示,還包括高壓氣體吹入機構800,其包括:On the basis of the foregoing
支撐杆810,固定在加塞位置上。The
吹氣環820,為空心的圓環,其內壁具有出氣孔821,通過管路和高壓氣源G連通,內徑大於或等於所述藥水瓶的瓶口而位於瓶口上。The
當預壓了覆著層的藥水瓶被所述輸送機構200輸送到處於加塞位置時,所述吹氣環即剛好處於瓶口上並進行吹氣,在所述吹氣環820朝具有弧形突起形狀的所述覆著層吹送高壓氣體時,所述加塞機構600將所述膠塞壓入瓶口。When the pre-compressed medicine bottle with the coating layer is transported to the stoppered position by the conveying
具體實施例20Specific Example 20
在上述實施例18和/或19的基礎上,所述出氣孔821是斜向下設置的,具體就是在吹氣環820的內壁上設置孔,然後焊接短管,將短管設置為斜向下。On the basis of the above embodiments 18 and/or 19, the air outlet 821 is arranged obliquely downward, specifically, a hole is provided on the inner wall of the
具體實施21
在上述實施例18和/或19和/或20的基礎上,所述支撐杆810是中空的管狀,起到管路的作用,一端與所述高壓氣源連通,另一端與所述吹氣環連通。On the basis of the above embodiments 18 and/or 19 and/or 20, the
具體實施例22Specific Example 22
在上述實施例18和/或19和/或20和/或21的基礎上,如圖13所示,其中,所述驅動元件510被設置在支架530上,支架530固定在預壓位置上。所述預壓模520包括壓環521以及套裝在該壓環內的陽模522。On the basis of the above-mentioned embodiments 18 and/or 19 and/or 20 and/or 21, as shown in FIG. 13, the driving
所述陽模522上端與第一驅動元件511連接,所述壓環521與第二驅動元件512連接。所述陽模522可在所述壓環521內上下滑動,其下端為凸起的弧面。The upper end of the
當藥水瓶被輸送到處於預壓位置時,所述第二驅動元件512驅動所述壓環521將放置在瓶口上的所述覆著層的邊緣壓緊固定在瓶口上,所述第一驅動元件511驅動所陽模522穿過所述壓環521下壓將所述覆著層22預壓成向下具有弧形突起的形狀。When the medicine bottle is transported to the pre-pressing position, the
具體實施例23Specific Example 23
在上述實施例18和/或19和/或20和/或21和/或22的基礎上,所述壓環521的底面設置有緩衝用的橡膠墊圈。On the basis of the above embodiments 18 and/or 19 and/or 20 and/or 21 and/or 22, the bottom surface of the
具體實施例24Specific Example 24
在上述實施例18和/或19和/或20和/或21和/或22和/或23的基礎上,所述第一驅動元件511、所述第二驅動元件512為氣缸或致動器或電磁鐵或電動推杆。On the basis of the above embodiment 18 and/or 19 and/or 20 and/or 21 and/or 22 and/or 23, the
由於第一驅動元件511是用於驅動陽模522進行壓膜的,而壓膜過程中陽模運動的快慢和力量大小將直接影響覆著層被壓成的形狀,過快或力量過大都將導致拉裂或拉斷,因此較佳推薦第一驅動元件511使用能精確控制力量大小和動作快慢的致動器(actuator),而且最好是伺服致動器。Since the
具體實施例25Specific Example 25
請參照圖11,AST-3424注射液的灌注加塞壓蓋裝置,包括上述具體實施例4-10中任意一項的具有突起的藥液包裝瓶的灌注加塞壓蓋裝置以及儲液箱C和該儲液箱連通的灌液管路(圖中未示出),其中,所述儲液箱C、所述灌液管路、所述灌液針頭310均為316號不鏽鋼部件;或所述儲液箱C、所述灌液管路、所述灌液針頭310的接觸藥液的內層均為聚偏氟乙烯層。Please refer to Figure 11, the filling, stoppering and capping device of AST-3424 injection includes the filling, stoppering and capping device of any one of the above-mentioned specific embodiments 4-10 of the medicinal solution packaging bottle with protrusions, and the liquid storage tank C and the The liquid filling pipe (not shown in the figure) connected with the liquid storage tank, wherein the liquid storage tank C, the liquid filling pipe, and the
具體實施例26Specific Example 26
在實施例24的基礎上,所述覆著層為聚偏氟乙烯層,On the basis of Example 24, the covering layer is a polyvinylidene fluoride layer,
所述送料機構400均為316號不鏽鋼部件;或 所述送料機構400接觸藥液的部件均塗覆有為聚偏氟乙烯層。The
具體實施例27Specific Example 27
如圖14所示,本實施例提供藥水瓶的灌注加塞壓蓋方法,依次包括灌液步驟S1、覆著層預壓步驟S2、加塞步驟S3以及壓蓋步驟S4。As shown in FIG. 14, this embodiment provides a method for filling, stoppering and capping of a medicine bottle, which sequentially includes a filling step S1, a coating pre-compression step S2, a stoppering step S3, and a capping step S4.
灌液步驟S1,通過灌液機構將預定體積的藥液灌注到藥水瓶中。In the liquid filling step S1, a predetermined volume of liquid medicine is poured into the liquid medicine bottle through the liquid filling mechanism.
覆著層預壓步驟S2,在藥液灌注到藥水瓶後,對覆著層進行預壓成型使得覆著層貼附在藥水瓶瓶口並形成向瓶口內突起的結構。In step S2 of pre-pressing the coating layer, after the medicinal solution is poured into the vial, the coating layer is pre-compressed and molded so that the coating layer is attached to the mouth of the vial and forms a structure protruding into the mouth of the bottle.
較佳的,在進行覆著層預壓時,將放置在瓶口上的覆著層固定後,使用陽模預壓。Preferably, when the coating layer is pre-compressed, the coating layer placed on the bottle mouth is fixed, and then a male mold is used for pre-compression.
加塞步驟S3,將膠塞快速的壓入貼附了覆著層的瓶口。快速是在0.1秒內或更快的速度。Stoppering step S3, quickly press the rubber stopper into the bottle mouth to which the coating layer is attached. Fast is within 0.1 seconds or faster.
壓蓋步驟S4,將鋁蓋直接壓到塞了膠塞的瓶口上,然後收緊鋁蓋的下端使得下端縮小變形而將膠塞牢固地固定在瓶口。In the capping step S4, the aluminum cap is directly pressed onto the bottle mouth plugged with the rubber stopper, and then the lower end of the aluminum cap is tightened so that the lower end is reduced and deformed to firmly fix the rubber stopper on the bottle mouth.
以下結合圖10以及圖14、16對整個裝置的工作過程進行介紹。The working process of the entire device will be introduced below in conjunction with Fig. 10 and Figs. 14 and 16.
整理洗淨的藥水瓶在理瓶機LB的料斗LD中被理瓶機的推杆慢慢的推送到卡盤220的卡口211中。然後被輸送機構200的卡盤輸送,在輸送到對應的灌液機構300對應的灌液位置時被灌液機構灌液(圖16中之a圖);The cleaned medicine bottle is slowly pushed into the
卡盤繼續旋轉,將灌液後的藥水瓶輸送至預壓位置後,送料機構400動作,將覆著層22放置在藥水瓶口(圖16中之b圖);The chuck continues to rotate, and after the liquid-filled medicine bottle is transported to the pre-pressing position, the
待放置後覆著層,覆著層預壓機構500的壓環521被驅動將覆著層的周邊固定在藥水瓶口上(圖16中之c圖),然後陽模522被驅動將覆著層預壓成型(圖16中之d圖);After the covering layer is placed, the
卡盤繼續旋轉,將藥水瓶運送到加塞位置,高壓氣體吹入機構800動作吹氣(圖10中之e圖),在高壓氣體吹入機構離開後加塞機構600將膠塞壓入(圖16中之f圖);The chuck continues to rotate to transport the medicine bottle to the stopper position. The high-pressure
當卡盤旋轉將壓塞後的藥水瓶輸送到壓蓋位置後,壓蓋機構700動作完成壓蓋(圖16中之g圖),保護蓋壓合機構BH隨即將保護蓋壓合(圖16中之h圖),最後得到圖2所示的包裝瓶。When the chuck rotates to transport the corked medicine bottle to the capping position, the
輸送機構200的卡盤繼續旋轉,將壓蓋後的藥水瓶輸送至出瓶機構900。The chuck of the conveying
如圖15所示,在料斗LD的邊沿設置有撥瓶板,該撥瓶板910呈朝向卡盤220的折線狀或弧狀,且其尖端伸入卡盤220的卡口221中,對應的該卡口的朝向該撥瓶板的一個邊緣設置有倒角(圓倒角或直角倒角),倒角的設計便於撥瓶板插入到卡口221中將藥水瓶撥出。As shown in Figure 15, a bottle-pull plate is provided on the edge of the hopper LD. The bottle-
當卡盤220繼續旋轉至出瓶機構900對應的位置時,撥瓶板910會將卡入卡口221的藥水瓶一個一個的撥出而進入到出瓶通道920中,如此即完成了出瓶過程。When the
1、10:瓶體
100:包裝瓶
1000:包裝套件
1002:包裝盒
1003:氣體保護袋
1500:灌注加塞壓蓋裝置
11:瓶身
12:瓶頸
121:凹陷
13:瓶口
2、21:膠塞
20:膠塞組件
200:輸送機構
210:主轉盤
211:基體
212:塞體
213:凹陷結構
214:封閉空腔
22:覆著層
220:卡盤
221:卡口
225:鼓包或突起
3、30:封蓋
300:灌液機構
31:缺口
310:灌液針頭
320:藥液定量開關
4、40:保護蓋
400:送料機構
41:圓柱形蓋部分
42:收頸部分
5:基體
500:覆著層預壓機構
510:驅動元件
511:第一驅動元件
512、522:壓環
520:預壓模
522:陽模
530:支架
6:塞體
600:加塞機構
7:覆膜
700:壓蓋機構
800:高壓氣體吹入機構
810:支撐杆
820:吹氣環
821:出氣孔
900:出瓶機構
910:撥瓶板
920:出瓶通道
BH:保護蓋壓合機構
C:儲液箱
G:高壓氣源
LB:理瓶機
LD:料斗
S1-S4:步驟1, 10: bottle body
100: packaging bottle
1000: Packing kit
1002: packing box
1003: Gas protection bag
1500: Filling, stoppering and capping device
11: Bottle body
12: bottleneck
121: sunken
13:
圖1為AST-3424藥物製劑的生產操作流程圖; 圖2為本發明的某些實施例中藥液包裝瓶的具體結構示意圖; 圖3為本發明的某些實施例中藥液包裝瓶的瓶體具體結構示意圖; 圖4為本發明的某些實施例中藥液包裝瓶的具體結構示意圖; 圖5為本發明的某些實施例中注射液的包裝瓶的膠塞元件具體結構示意圖; 圖6為本發明的實施例中「變形壓合」的操作來進行壓合覆膜的過程示意圖; 圖7為本發明的某些實施例中包裝套件的結構示意圖; 圖8為習知技術中典型的藥水瓶的結構示意圖; 圖9為習知技術中典型的覆膜膠塞的結構示意圖; 圖10為本發明的某些實施例中灌注加塞壓蓋裝置的結構示意圖; 圖11為本發明的某些實施例中灌液機構的結構示意圖; 圖12為本發明的某些實施例中高壓氣體吹入機構的結構示意圖; 圖13為本發明的某些實施例中覆著層預壓機構的結構示意圖; 圖14為本發明的某些實施例中藥水瓶的灌注加塞壓蓋方法步驟示意圖; 圖15為本發明的某些實施例中出瓶機構的結構示意圖;以及 圖16為使用本實施例提供的灌注加塞壓蓋裝置進行藥水瓶的灌注加塞壓蓋的動作示意圖。Figure 1 is the production flow chart of AST-3424 pharmaceutical preparations; Figure 2 is a schematic diagram of a specific structure of a liquid medicine packaging bottle in some embodiments of the present invention; 3 is a schematic diagram of the specific structure of the body of the liquid medicine packaging bottle in some embodiments of the present invention; 4 is a schematic diagram of a specific structure of a liquid medicine packaging bottle in some embodiments of the present invention; 5 is a schematic diagram of the specific structure of the rubber stopper element of the packaging bottle for injection in some embodiments of the present invention; 6 is a schematic diagram of the process of laminating the film by the operation of "deformation and pressing" in the embodiment of the present invention; Figure 7 is a schematic structural diagram of a packaging kit in some embodiments of the present invention; Figure 8 is a schematic structural diagram of a typical medicine bottle in the prior art; Figure 9 is a schematic diagram of the structure of a typical film-coated rubber stopper in the prior art; Figure 10 is a schematic structural diagram of a filling, plugging and capping device in some embodiments of the present invention; Figure 11 is a schematic structural diagram of a filling mechanism in some embodiments of the present invention; Figure 12 is a schematic structural view of a high-pressure gas blowing mechanism in some embodiments of the present invention; Figure 13 is a schematic structural view of a pre-compression mechanism for a covering layer in some embodiments of the present invention; 14 is a schematic diagram of the steps of a method for filling, stoppering and capping of a medicine water bottle in some embodiments of the present invention; 15 is a schematic diagram of the structure of the bottle ejecting mechanism in some embodiments of the present invention; and FIG. 16 is a schematic diagram of the action of filling, plugging and capping of the vial by using the filling, stoppering and capping device provided by this embodiment.
10:瓶體10: Bottle body
11:瓶身11: Bottle body
12:瓶頸12: bottleneck
13:瓶口13: Bottle mouth
121:凹陷121: sunken
20:膠塞組件20: Rubber plug assembly
211:基體211: Matrix
213:凹陷結構213: Recessed structure
214:封閉空腔214: closed cavity
22:覆著層22: Overlay
30:封蓋30: capping
31:缺口31: gap
40:保護蓋40: Protective cover
41:圓柱形蓋部分41: Cylindrical cover part
42:收頸部分42: Neck part
Claims (28)
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201921470760.3U CN210653722U (en) | 2019-09-05 | 2019-09-05 | Pouring, plugging and capping device for liquid medicine packaging bottle with protrusion |
CN201910837741.8A CN111572833B (en) | 2019-09-05 | 2019-09-05 | Filling, plugging and capping device and method for liquid medicine packaging bottle with protrusions |
CN201910837201.X | 2019-09-05 | ||
CN201921470755 | 2019-09-05 | ||
CN201921470755.2 | 2019-09-05 | ||
CN201921470760.3 | 2019-09-05 | ||
CN201910837741.8 | 2019-09-05 | ||
CN201910837201.XA CN111568759B (en) | 2019-09-05 | 2019-09-05 | Packaging bottle for AST-3424 injection and packaging kit and method |
Publications (1)
Publication Number | Publication Date |
---|---|
TW202110415A true TW202110415A (en) | 2021-03-16 |
Family
ID=74852777
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW109130514A TW202110415A (en) | 2019-09-05 | 2020-09-04 | Packaging bottle and packaging kit for injection, and filling, stoppering and capping device and method |
Country Status (2)
Country | Link |
---|---|
TW (1) | TW202110415A (en) |
WO (1) | WO2021043275A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI785989B (en) * | 2022-02-21 | 2022-12-01 | 長庚學校財團法人長庚科技大學 | Portable Chemotherapy Vials |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2294937A1 (en) * | 1974-12-18 | 1976-07-16 | Neve Rene | Two-compartment bottle for two-component pharmaceutical prods. - which must be kept apart until the moment of injection |
CN2441750Y (en) * | 2000-06-23 | 2001-08-08 | 程继勇 | Rubber bottle cap for surface film coated medicine |
CN1431141A (en) * | 2003-02-20 | 2003-07-23 | 长沙楚天包装机械有限公司 | High-speed machine for filling in liquid and adding plugs |
CN203997487U (en) * | 2014-01-08 | 2014-12-10 | 中国大冢制药有限公司 | The plastic ampoule packing of sodium bicarbonate injection |
CN105662859A (en) * | 2016-03-29 | 2016-06-15 | 江苏华兰药用新材料股份有限公司 | Laminating rubber plug and production method thereof |
CN111572833B (en) * | 2019-09-05 | 2024-02-09 | 深圳艾欣达伟医药科技有限公司 | Filling, plugging and capping device and method for liquid medicine packaging bottle with protrusions |
CN116942524A (en) * | 2019-09-05 | 2023-10-27 | 深圳艾欣达伟医药科技有限公司 | Packaging bottle for AST-3424 injection and packaging kit and method |
CN210653722U (en) * | 2019-09-05 | 2020-06-02 | 深圳艾欣达伟医药科技有限公司 | Pouring, plugging and capping device for liquid medicine packaging bottle with protrusion |
-
2020
- 2020-09-04 TW TW109130514A patent/TW202110415A/en unknown
- 2020-09-04 WO PCT/CN2020/113550 patent/WO2021043275A1/en active Application Filing
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI785989B (en) * | 2022-02-21 | 2022-12-01 | 長庚學校財團法人長庚科技大學 | Portable Chemotherapy Vials |
Also Published As
Publication number | Publication date |
---|---|
WO2021043275A1 (en) | 2021-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10781027B2 (en) | Packaging system for oxygen-sensitive drugs | |
EP2920567B1 (en) | Method and apparatus for detecting rapid barrier coating integrity characteristics | |
US10279119B2 (en) | Safety syringe and methods for administration of a medicament dose by subject weight | |
CN111568759B (en) | Packaging bottle for AST-3424 injection and packaging kit and method | |
US20200253827A1 (en) | Drug mixer, hard dual-port member, and soft infusion bag | |
WO2016013049A1 (en) | Packaged acetaminophen injection solution preparation | |
CN102482023A (en) | Packaged products, inserts and compartments for aseptic mixing of substances, along with methods for use therewith | |
CN104159622A (en) | Medical device package | |
FI105450B (en) | Apparatus and method for dosing a liquid product | |
CN210653722U (en) | Pouring, plugging and capping device for liquid medicine packaging bottle with protrusion | |
US20090264834A1 (en) | Rigid double-port tube with medicine dispensing nozzle for the big transfusion soft bag | |
WO2021043275A1 (en) | Packaging bottle and packaging kit for injection, and filling, stoppering and capping device and method | |
CN111573604B (en) | System and method for preparing, filling, plugging and capping AST-3424 injection | |
US10195112B2 (en) | Adaptor for multidose medical container | |
CN111572833B (en) | Filling, plugging and capping device and method for liquid medicine packaging bottle with protrusions | |
CN210683189U (en) | Preparation, filling, plugging and capping system for AST-3424 injection | |
CN213822550U (en) | Injection packaging bottle and packaging kit | |
CN210708001U (en) | Preparation, filling, plugging and capping system of AST-3424 injection with bottle outlet mechanism | |
CN210708002U (en) | AST-3424 injection filling, plugging and capping device with bottle outlet mechanism | |
KR20210038879A (en) | Method and drug filling device for filling at least one degassed drug in containers | |
JP2578425B2 (en) | Plastic container with rubber stopper | |
JPH0910281A (en) | Mouth part structure for medicine container | |
CN2717434Y (en) | Soft bag infusion filling medicine plug | |
JP2001124671A (en) | Housing body for analyzing gas |